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Metastatic melanoma is responsible for almost 80% of all skin cancer-related deaths and 
the incidence of people affected continues to rise worldwide. The emergence of targeted 
therapy and immune-checkpoint inhibitors has improved the clinical management of 
melanoma, but durable survival benefit is only seen in a minority of patients. The use of 
these very expensive systemic therapies on all appropriate patients also poses a high 
economic burden on health systems across numerous countries. Currently, surveillance 
for treatment failure is not optimal. Thus, reliable and accurate biomarkers of patient 
disease status are urgently required. 
Circulating tumour DNA (ctDNA) analysis has emerged as a potential “liquid biopsy” for 
melanoma. Plasma-derived ctDNA are short DNA fragments released into the 
bloodstream by apoptotic tumour cells. Studies have shown that ctDNA levels in blood 
correlate with tumour burden and can comprehensively capture the molecular 
heterogeneity of melanoma metastases. Thus, ctDNA appears to be a viable biomarker for 
monitoring treatment response and disease progression in melanoma patients. However, 
further studies aimed at comparing ctDNA and current standard clinical assessments are 
needed to fully define its suitability as a complementary test to guide treatment decisions. 
This thesis aims to provide important information that will assist with the 
implementation of ctDNA as a biomarker for melanoma in the clinical management of the 
disease. This thesis is comprised of 7 chapters: a comprehensive literature review 
(Chapter 1. Introduction); a materials and methods chapter (Chapter 2); 4 results 
chapters (Chapter 3 – 6); and a final chapter with a general discussion of main findings 
and future directions (Chapter 7. General Discussion and Future Directions). 
The first chapter of the thesis includes a thorough review of the literature on ctDNA as a 
potential biomarker for melanoma disease (Chapter 1). This is then followed by a detailed 
description of our protocol for plasma ctDNA extraction and quantification using droplet 
digital PCR (Chapter 2). Using this methodology, we evaluated the ctDNA detection rate 
in untreated BRAF mutant melanoma patients, as a potential alternative to tumour 
genotyping (Chapter 3), where the potential economic benefit of implementing plasma 
ctDNA testing by ddPCR relative to tissue BRAF testing was also investigated. 
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The study in Chapter 4 demonstrated that pre-treatment plasma ctDNA is predictive of 
patient outcomes in the first-line treatment setting. However, baseline ctDNA level was 
not predictive of outcomes in the second-line immunotherapy setting, especially in 
patients that were pre-treated with BRAF/MEK inhibitors. Moreover, we found 
preliminary evidence that patients with high pre-treatment ctDNA may benefit from 
combined anti-CTLA-4/anti-PD-1 therapy. 
Chapter 5 discusses the validity of ctDNA as a surveillance biomarker for melanoma. The 
kinetics of ctDNA decline were found delayed in patients treated with immunotherapy 
compared to those receiving MAPK inhibitors. Nonetheless, decreasing ctDNA levels 
within 12 weeks of immunotherapy or BRAF/MEK inhibitors was strongly concordant 
with treatment response and significantly associated with longer progression-free 
survival (PFS). Furthermore, exploratory analysis of nine patients commencing anti-PD-
1 therapy showed a trend of high tumour mutational burden (TMB) and neoepitope load 
in responders compared to non-responders. 
Chapter 6 evaluates the validity of ctDNA to accurately detect disease progression using 
both a retrospective and a prospective cohort of melanoma patients. The results indicated 
a moderate detection rate, suggesting that more sensitive methodologies are required to 
achieve a limit of detection comparable to current medical imaging. 
Finally, Chapter 7 provides a general discussion of the studies covered in this thesis. It 
underscores the clinical validity of ctDNA as a biomarker of prognosis and therapeutic 
response in melanoma patients, while highlighting important limitations inherent to 
ctDNA analysis that need to be thoroughly addressed before it can be successfully 
implemented in the clinic. 
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CHAPTER 1. INTRODUCTION AND LITERATURE REVIEW 
1.1 Introduction 
Melanoma is an aggressive cutaneous cancer responsible for the majority of skin cancer-
related deaths [1, 2]. In addition, the incidence of melanoma is increasing worldwide, 
which results in significant costs to the healthcare systems [3]. Generally, patients are 
considered cured after complete surgical resection of the primary tumour [4]. 
Nevertheless, around 20% of patients will develop metastatic disease, which is extremely 
difficult to treat [5]. 
In the last ten years, the use of targeted therapies and immunotherapies has improved 
the survival of metastatic melanoma patients. However, the low response rate to 
immunotherapies and the risk of developing resistance to both targeted and 
immunotherapies contribute to the sub-optimal prognosis for most metastatic patients. 
Moreover, adverse side-effects associated with current immunotherapies restrict 
treatment efficacy in some cases [6]. Therefore, new biomarkers are urgently needed for 
personalised monitoring of the disease, with the aim to determine treatment response 
and recurrence at earlier stages. This will allow optimal selection and/or timely 
treatment modification to improve survival rates in patients. 
Plasma ctDNA are short DNA fragments released into the bloodstream by the tumours 
within a patient. Since ctDNA can be detected in the blood of melanoma patients, these 
DNA fragments can be used as a “liquid biopsy”, providing critical insight into each 
person’s melanoma status. Studies have previously shown that ctDNA levels correlate 
with tumour burden and disease stage, characteristics that have been exploited in 
different cancer types to determine the clinical value of ctDNA in monitoring clonal 
evolution and identifying mechanisms of resistance [7-10]. Outcomes of these studies 
have driven the Food and Drug Administration (FDA) and European Medicines Agency 
(EMA) to approve the analysis of ctDNA in patients with non-small cell lung cancer 
(NSCLC) to identify patients carrying a specific mutation that makes them resistant to 
first-line treatment [11]. 
Plasma ctDNA in melanoma has been defined as a biomarker of disease status used to 
monitor clonal evolution, detect the emergence of resistance to treatment and predict 
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response to therapy [12-16]. Detection of BRAF mutations in plasma cfDNA has been 
associated with higher disease burden and worse prognosis. Similarly, the presence of 
BRAF or NRAS mutation prior to or during systemic treatment has been associated with 
larger tumours, increased lactate dehydrogenase (LDH) levels, and development of brain 
metastases [17]. Studies investigating circulating tumour DNA (ctDNA) have been 
conducted mainly in small cohorts of patients treated with targeted therapies and only a 
few studies have focused on BRAF wild-type patients treated with immunotherapy. 
Constant changes in the pharmacotherapies used in melanoma have shaped an urgent 
need to effectively evaluate the detection rate of ctDNA in large cohorts and assess its 
proficiency to inform response to therapy and progressive disease. Further studies are 
needed to compare this biomarker with current standard clinical assessments and to 
assess its suitability as a complementary test that guides treatment decisions. 
1.2 Cutaneous Melanoma 
The skin is the largest organ in the body and serves to protect us from ultraviolet (UV) 
light, injuries and infections, among other important functions [18]. The main layers of 
the skin include the subcutaneous layer, the dermis, and the epidermis. The epidermis is 
the outermost layer and contains three different types of skin cells: squamous cells, basal 
cells, and melanocytes. Melanocytes are in the basal layer of the epidermis and are 
responsible for melanin pigment production (Figure 1.1). 
 
Figure 1.1. Representation of normal skin anatomy. Melanocytes are present in the basal layer of 
the epidermis. Retrieved from Winslow et al. [19]. 
Image is available online at https://www.teresewinslow.com/#/skin/
22 
 
Cutaneous Melanoma is a highly aggressive skin tumour originating from the neoplastic 
transformation of melanocytes. Melanoma occurs principally in the skin but may also 
develop in the conjunctiva and uvea of the eye (uveal melanoma), on various mucosal 
membranes with pigmented tissues, such as the gastrointestinal tract, oral or genital 
membranes, meninges, and in internal organs, such as in the central nervous system [20]. 
1.2.1 Epidemiology 
Cutaneous melanoma is the most lethal form of skin cancer responsible for approximately 
80% of skin cancer deaths despite representing only <5% of all dermatological 
neoplasms [21]. The incidence of melanoma is increasing worldwide, but New Zealand 
and Australia continue to have the highest incidence and mortality rates [22, 23]. In 
Australia, melanoma was the 3rd most commonly diagnosed cancer in 2019 and new cases 
of melanoma skin cancer are estimated to increase to 16,221 in 2020 with approximately 
1,375 estimated deaths [1] (Figure 1.2). In fact, the Australian melanoma health 
expenditure each year is the highest in the world relative to the population [24]. 
Moreover, melanoma accounts for 11% of all newly diagnosed cancers [1]. The 
anatomical location of the primary melanoma is commonly found in the trunk in men and 
the extremities in women [25]. The location of the tumour also varies with age, being on 
the trunk or extremities more commonly in younger ages, but on head and neck locations 
in advanced ages [26, 27]. 
 
Figure 1.2. Age-standardised incidence rates for melanoma skin cancer 1982–2013 and age-
standardised mortality rates for melanoma skin cancer 1968–2014, by sex, in Australia. Retrieved 




Sun exposure is a major risk factor associated with cutaneous melanoma formation. UV 
radiation induces the formation of mutagenic cyclobutane pyrimidine dimers. A 
significant number of melanoma-associated genes bear UV-induced signature C>T 
transition mutations in cellular DNA [28-32]. Melanoma also has the highest median 
number of somatic mutations across all human cancer types [33]. 
Trends in melanoma incidence show that Caucasian race, male gender, and older age are 
characteristics associated with an increased risk of developing melanoma [34]. Also, fair-
skinned individuals with red or blond hair and many freckles are more likely to suffer 
from the disease [35, 36]. Having a higher number of benign melanocytic naevi, atypical 
naevi or giant congenital naevi also increases the risk of developing melanoma [37, 38]. 
Other host factors such as a personal history of melanoma or non-melanoma tumours, 
including other skin cancers, can increase the risk of developing melanoma [39-41]. 
Moreover, a weak immune system or having a disease that weakens the immune system, 
increases the cancer risk, with a higher incidence of cutaneous melanoma in patients after 
organ transplantation proposed to be due to medical immunosuppression [42]. 
Genetic predisposition is also a factor involved in melanoma development. About 10% of 
all melanomas are estimated to be due to hereditary susceptibility [43]. Since William 
Norris [44] first suggested that melanomas have a hereditary component, the knowledge 
of melanoma genetics has advanced significantly. It is now known that having a family 
history of melanoma increases the risk 1.74 times compared with a negative family 
history of the disease [45]. Inherited genetic risk factors can be classified by their 
penetrance and prevalence [46]. 
Rare but highly penetrant genetic mutations in CDKN2A and CDK4 genes are commonly 
found in high-risk melanoma families [47]. These genes are involved in cell-cycle 
regulation and melanocyte senescence. As an example, the CDKN2A gene located on 
chromosome 9p21.3, encodes two proteins. p14ARF and p16INK4A, which control cell 
cycle entry at the G1 checkpoint and stabilise p53 expression [48]. Low melanoma 
penetrance mutations present in the general population, often referred to as single 
nucleotide polymorphisms (SNPs), have also been detected in genes involved in hair and 
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skin pigmentation, such as MC1R, ASIP, TYR and TYRP1 [49-52]. In addition, SNPs in BAP1, 
POT1, ACD, TERF2IP, and TERT are also considered risk genes for inherited melanoma 
[53]. 
1.2.3 Diagnosis 
The first step in melanoma diagnosis is the visual characterisation of suspicious lesions. 
Nonetheless, diagnosis of melanoma is often complicated by the resemblance of early 
stage melanoma to naevi, which are chronic lesions found in the skin or mucosa [54]. 
While naevi are often considered benign, more than 20% of malignant melanomas arise 
from pre-existing naevi [55]. Visual characteristics of a transformed mole can be 
identified via the “ABCDE criteria”: Asymmetry, a Border that is irregular, Colour that is 
uneven, a Diameter longer than 6 millimetres and, a shape, size or colour that is Evolving 
(Figure 1.3). Other early signs of a malignant change are itching, ulceration or bleeding. 
By contrast, nodular melanomas do not follow these criteria. They have their own "EFG 
criteria"; the lesion is Elevated above the surrounding the skin, the nodule is Firm to the 
touch and Growing in size. 
Figure 1.3. Melanomas with characteristic asymmetry, border irregularity, colour variation and 
large diameter. Retrieved from the National Cancer Institute [56]. 
The majority of abnormal lesions/naevi/moles are primarily detected through skin 
examination and assessed using dermoscopic tools that can differentiate melanoma from 
other types of carcinoma or benign lesions [57]. Some of the diagnostic techniques 
available for better identification of skin cancer include; total body photography [58], 
multispectral imaging, confocal scanning laser microscopy, ultrasound imaging [59], 
magnetic resonance imaging [60], and optical coherence tomography. A histological 




examination of a tissue biopsy from a suspected lesion is necessary to confirm melanoma 
diagnosis and tumour staging. The histopathological criteria of melanoma are based on 
abnormal characteristics of the lesion such as ulceration, the extent and penetrance of 
the tumour, and the mitotic rate of the cells in the lesion. 
The discovery of histologic markers that uniquely identify melanocytes in melanoma has 
aided melanoma diagnosis. The most commonly used markers are S100 [61], MART-
1/Melan-A [62], HMB-45 [63, 64], SOX-10 [65] and MC1R [66]. Currently, a combination 
of multiple positive histologic markers and histopathologic criteria provides the most 
reliable method of diagnosis. If melanoma cells are detected in a lesion, the spread of the 
disease will be further assessed, to stage the melanoma. 
1.2.4 Staging of melanoma 
To determine the optimal treatment strategy and the prognosis of a patient with 
melanoma, staging of the biopsied material is needed. The American Joint Commission on 
Cancer (AJCC) updated the melanoma classifications in 2017 [67] using the most 
significant prognostic values as shown in Table 1.1. The clinical staging of melanoma is 
based primarily on the micro-staging of the excised tumour and the clinical and 
radiological examination of the regional lymph nodes and distant organ involvement. 
Patients are then classified into five main groups. In patients with stage 0 (in situ 
melanoma), melanoma is confined to the epidermis and has not invaded deeper skin 
layers. Patients with clinical stages I and II, are those with primary melanoma and no 
evidence of metastases. Stage III is indicated for patients with evidence of regional lymph 
node metastases. Lastly, stage IV melanoma patients are those that have been diagnosed 
with one or more distant metastases [68]. Pathological staging includes micro-staging of 
the primary melanoma and pathological information about the regional lymph nodes 
after lymph node biopsy. Both clinical and pathological staging are important in 
melanoma diagnosis and treatment decisions. 
The TNM classification is used to stage patients based on the extent of the primary 
tumour (T), the presence or not and the extent of regional lymph node metastases and 
non-nodal locoregional sites, such as in-transit, satellite and/or microsatellite metastases 
(N), and the presence or absence of distant metastases (M) [69]. 
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Table 1.1. Classification of the pathological stage and the main features related to melanoma 















5 years 10 years 
0 Tis - - 0 - - ≥99 ≥99 
IA T1a <0.8 No 0 - - 99 98 
 T1b 
<0.8 
0.8 - 1.0 
Yes 
Yes/No 
0 - - 99 96 
IB T2a >1.0 - 2.0 No 0 - - 96 92 
IIA T2b >1.0 - 2.0 Yes 0 - - 93 88 
 T3a >2.0 - 4.0 No 0 - - 94 88 
IIB T3b >2.0 - 4.0 Yes 0 - - 86 81 
 T4a >4.0 No 0 - - 90 83 
IIC T4b >4.0 Yes 0 - - 82 75 
IIIA N1a- <0.8 
0.8 - 1.0 
>1.0 - 2.0 
Yes/No 
1 Occult - 
93 88 




>1.0 - 2.0 

















































≥1 App. MN 

















≥1 App. MN 










1- ≥4 Any Any 
IIID N3a >4.0 Yes ≥4 Occult - 
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 N3b >4.0 Yes ≥4 ≥1 App. MN - 





IV M1a Any Any Any Any Skin n/a n/a 
 M1b Any Any Any Any Skin; Lung n/a n/a 
 M1c Any Any Any Any Other; Non-CNS Visceral n/a n/a 
 M1d Any Any Any Any Other; CNS Visceral n/a n/a 
The N category defines the number of clinically occult or clinically apparent regional 
nodes or macro-metastatic nodes determined by standard immunohistochemical 
staining using melanocytic markers. The presence of intra-lymphatic metastases 
including the presence or absence of satellites or in-transit metastases are also taken into 
consideration in this category. Regional nodal metastasis is defined as a disease confined 
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to one nodal basin, while patients with distant nodal metastases will be classified as 
having M stage disease [69]. 
The M category defines the presence of distant metastases in the skin, subcutaneous 
tissue, or distant lymph nodes or organs. Importantly, based on the anatomic sites of 
metastasis, patients are assigned into 4 M subcategories: M1a, M1b, M1c, and M1d. 
Patients with distant metastasis to the skin, subcutaneous tissue, muscle, or distant 
lymph nodes are categorized as M1a. Patients with metastasis to lung (with or without 
M1a disease) are categorized as M1b. Patients with metastases to any other visceral 
site(s) (excluding central nervous system (CNS) disease) are designated as M1c, while 
patients with metastases to the CNS are designated as M1d. 
Cutaneous melanomas are also subdivided into several subtypes, based on common 
anatomical locations and different patterns of growth. Superficial spreading melanoma is 
the most frequent, followed by nodular melanoma, acral lentiginous melanoma and 
lentigo maligna melanoma [71]. 
1.2.5 Genetic and histopathological changes in melanoma development 
As explained above, both genetic predisposition and exposure to environmental agents 
are risk factors for melanoma development. It is important to highlight that melanocyte 
malignant transformation involves the progressive accumulation of mutations in genes 
that are involved in cell-cycle control, proliferation, differentiation, and cell death [72], 
until finally, melanoma cells acquire the ability to initiate and sustain angiogenesis. This 
process, by which melanocytes progress to a malignant phenotype through several steps, 
is known as melanomagenesis [73] (Figure 1.4). 
Based on the pattern of the most prevalent and significant mutated genes, melanomas 
can be classified into four genomic sub-types: mutant BRAF, mutant NRAS, mutant 
neurofibromin type 1 (NF1), and triple wild-type (WT; Figure 1.5) [74]. Molecular 
classification of melanomas is important as it can guide treatment strategies. 
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Figure 1.4. Biologic events that take place in melanoma progression. The benign nevus 
commences a dysplastic transformation, through radial and vertical growth until the metastatic 
phenotype arises. Adapted from Miller et al. [5]. 
The RAS/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) signal transduction 
pathway is one of the most important pathways in the origin and progression of 
melanoma. BRAF is a member of the RAF family of serine-threonine kinases, along with 
ARAF and CRAF (also called RAF1). Mutations in the BRAF gene have been described in 
40-60% [75, 76] of all melanoma cases. Among mutations in the BRAF gene, 
approximately 80% of the mutations result in the substitution of glutamic acid (E) for 
valine (V) in codon 600, known as the BRAF V600E mutation. About 16% of mutations in 
this gene result in a lysine (K) substitution at the same BRAF V600K codon, and 3% result 
in an aspartic acid (D) or arginine (R) substitution that produces a V600D/R codon [77]. 
These last two mutant forms of BRAF tend to be present in melanomas arising in older 
patients [78]. All of these mutations occur as early events in melanomagenesis and result 
in a mutant protein that is constitutively active in the cell without the need for activation 
signals. The consequence is uncontrolled proliferation and resistance to apoptosis. 
Nevertheless, the presence of BRAF mutations in 80% of benign naevi suggests that 
mutational activation of the MAPK pathway is a critical step in melanocytic 
transformation but alone is insufficient for melanoma tumourigenesis [79]. 
Image is available (Figure 2) at https://www.nejm.org/doi/full/10.1056/NEJMra052166
29 
 
Mutations in the NRAS gene are present in approximately 15 to 20% of all cutaneous 
melanomas [80]. Commonly, NRAS mutations occur in codon 61, resulting in replacement 
of a glutamine residue by an arginine (Q61R) or lysine (Q61K) in the protein. However, 
other forms of NRAS mutations result in a substitution of glutamine at position 61 by 
leucine (Q61L) or histidine (Q61H) or substitution of glycine at position 12 or 13 by 
aspartic acid (G12D/G13D). Mutated NRAS results in constitutive activation of the MAPK 
signalling pathway resulting in increased cell proliferation and advancement of tumour 
growth. Tumours that carry NRAS mutations represent a distinct subpopulation from 
mutant BRAF melanomas, since BRAF and NRAS mutations are generally mutually 
exclusive [81, 82]. Together, NRAS and BRAF mutations are present in about 70% of the 
most common types of melanoma [74]. 
NF1 is the third most commonly mutated gene in melanoma and is present in up to 46% 
of BRAF and NRAS wild-type melanomas or ~12-18% of all melanomas. NF1 shows a high 
frequency of non-silent exonic mutations and a low frequency of synonymous or intronic 
mutations but there are no hot spot mutations in NF1 [83]. This tumour suppressor gene 
encodes for a direct negative regulator of RAS, which cooperates with mutated BRAF in 
melanomagenesis [84]. 
Figure 1.5. Frequency and mutation subtypes associated with melanoma. Retrieved from the 
Cancer Genome Atlas [74]. 
Another important genetic alteration present in melanoma is found on a well-
characterised tumour-suppressor, the phosphatase and tensin homolog (PTEN) gene. 
The encoded protein is a key initiator of the PI3K signalling pathway. Somatic PTEN 
mutations or deletions have been identified in 10-30% of melanomas [74, 85]. Loss of 
PTEN frequently coexists with BRAF mutations, but not with mutant NRAS, which can 
activate the PI3K pathway independently. 
Image is available (Figure 1 - middle section of A) at https://doi.org/10.1016/j.cell.2015.05.044
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The Ras-related C3 botulinum toxin substrate 1 (RAC1) gene encodes for an RHO GTPase 
protein which plays a key role in cellular cytoskeleton organization. Dysregulation of 
RAC1 leads to cell proliferation and suppression of antitumor immune responses [86]. A 
recurrent mutation at codon 29 (P29S) of RAC1 that leads to a proline-to-serine 
conversion has been identified in 5% to 9% of melanomas. 
The telomerase reverse transcriptase (TERT) gene encodes for a catalytic subunit of the 
holoenzyme telomerase, which sustains telomere length and chromosomal stability. 
Reactivation of the TERT gene enables cells to overcome replication-induced senescence, 
a critical step in tumour initiation. There are two recurrent mutations, located within 100 
base pairs of the TERT transcriptional start site on chromosome 5; cysteine-to-threonine 
mutations at codon 228 (C228T) and codon 250 (C250T). These mutations are consistent 
with an ultraviolet signature (C>T or CC>TT), thus implicating a role for ultraviolet 
radiation in their induction. These mutations have been identified in sporadic primary 
melanomas (33%), metastatic melanomas (85%), and melanoma cell lines (76%) [87]. In 
addition, 55% of melanomas have TERT mutations co-existing with BRAF or NRAS 
mutations [88]. 
Melanomas may also carry mutations that activate the KIT receptor protein tyrosine 
kinase, tumour protein 53 (TP53) or cyclin-dependent kinase inhibitor 2A (CDKN2A). The 
KIT gene is located on the long (q) arm of chromosome 4. Most KIT mutations are located 
in exon 11, which encodes for the juxtamembrane domain, and in exon 13, which encodes 
for a kinase domain [89]. Mutations in TP53 are prevalent in approximately 20% of 
melanomas [90] and CDKN2A, which encodes for the p16INK4A protein, is found mutated 
in approximately 30% to 40% of familial melanomas [91, 92]. Altogether, studies have 
shown that BRAF, CDKN2A, NRAS and TP53 are significantly mutated in cutaneous 
melanoma; BRAF, NRAS and NF1 in acral melanoma, and SF3B1 in mucosal melanoma 
[93]. 
1.2.6 Progression 
Metastatic melanoma can be distinguished as either a local recurrence, in-transit 
metastasis, nodal metastasis and/or distal metastasis, based on the morphological 
characteristics and location. Local recurrence is defined as a recurrence of melanoma 
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within 2 cm of the surgical scar of a primary melanoma [94]. This recurrence can result 
from either the extension of the primary melanoma or from the spread via lymphatic or 
haematogenous vessels [95]. In-transit metastasis is defined as melanoma deposits 
within the lymphatic vessels located more than 2 cm from the site of the primary 
melanoma. Nodal metastasis involves the spread of tumour cells into the lymph nodes. 
Haematogenous spread of metastatic melanoma results in the development of distal 
metastasis [96]. 
A variety of sophisticated imaging techniques are now used to follow and evaluate 
patients with melanoma, including chest radiographs, regional nodal ultrasound imaging, 
computerised tomography (CT) scans, positron emission tomography (PET), PET/CT 
scans, and brain/spine and hepatic magnetic resonance imaging (MRI) to detect nodal 
disease and distant metastases [68, 97]. Among all these modalities, PET scans have 
shown an improved performance in depicting metastatic lesions over conventional 
imaging modalities, such as CT has been commonly described in the literature [98, 99]. 
In addition, LDH blood levels have been considered an important prognostic marker for 
patients with stage IV disease [100]. However, LDH levels are highly affected by other 
normal biological processes including inflammation and tissue damage. Therefore, new 
biomarkers are required to identify patients likely to develop distant metastases. 
1.2.7 Treatment and prognosis 
The standard treatment for in situ and primary melanoma is wide local excision (WLE) of 
the skin and subcutaneous tissues around the melanoma. Surgical removal of melanoma 
offers the best chance for a complete cure and is usually successful in patients categorised 
as stage 0, I and stage II. Most patients do not need either radiotherapy or chemotherapy 
since the tumour is still localised and there are no other existing metastases. However, 
greater tumour thickness is associated with an increased risk of local recurrence [101]. 
WLE is the treatment of choice in local recurrences, with consideration given to adjuvant 
therapy in some situations [68], since there is an increased risk of systematic or regional 
metastasis. 
Currently, sentinel lymph node biopsies are carried out in patients with melanomas 
thicker than 1mm, or >0.8mm if the tumour is ulcerated [67, 102]. If the result is positive, 
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the patient will be diagnosed with melanoma stage III. Since patients with positive lymph 
nodes are at high risk of systemic dissemination, a therapeutic lymph node dissection 
may be considered. However, the MSLT-I study together with the Cochrane Review found 
no improved melanoma-specific survival for patients with intermediate or thick 
melanomas treated with a sentinel lymph node biopsy [103, 104]. In addition, adjuvant 
treatment with targeted therapies and immunotherapies is the standard of care due to 
their proven increase in survival and delayed disease recurrence [105, 106]. 
In regards to prognosis, the main clinical and histopathologic predictors of outcome are 
Breslow’s thickness, the presence of ulceration, the sentinel lymph node status [107] and 
the presence of distant metastases. 
The choice of therapy for the management of unresectable or metastatic melanoma 
depends on the number of lesions present within a patient, as well as the anatomical 
location, and size of the lesions. Treatment for metastatic melanoma aims to control the 
melanoma and to relieve any symptoms, with curable intentions. When surgery is not 
possible, treatments such as targeted therapies, immunotherapy, chemotherapy, 
radiotherapy and diverse clinical trials of these and other new drugs individually or in 
combination are available. Since 2011, treatment combinations using targeted therapy 
and/or immunotherapy have revolutionised the clinical management of melanoma 
patients, improving the length of survival of patients with stage III or stage IV melanoma 
[108-110]. 
Targeted Therapy 
Since the discovery of the presence of activating mutations in the BRAF oncogene in 
approximately 50% of melanomas [75], there has been notable progress in the 
development of targeted therapies for unresectable and metastatic melanoma of patients 
carrying this mutation [111]. The FDA approved the use of BRAF inhibitors vemurafenib, 
dabrafenib and encorafenib as first line therapy for BRAF positive metastatic or 
unresectable melanoma [112, 113]. 
The great success of BRAF inhibitors in some patients and at the same time, the disease 
relapse in other patients treated with BRAF inhibitors, prompted the development of 
MEK inhibitors to further inhibit the MAPK signalling pathway at the next downstream 
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MEK1/2 activation point. Nowadays, the FDA approved MEK inhibitor trametinib, is less 
commonly indicated as a monotherapy, being used more commonly in combination with 
dabrafenib. The other FDA-approved MEK inhibitor, cobimetinib, is indicated for use in 
combination with vemurafenib [114]. Additional MAPK targeted drugs have been 
developed, such as BRAF inhibitor, encorafenib and MEK inhibitor, binimetinib. Results 
from an open-label phase III COLUMBUS trial showed that encorafenib and binimetinib 
combination offer longer median PFS and OS than vemurafenib monotherapy [115]. 
As a result of the positive outcomes from the clinical trials involving these combination 
therapies (Figure 1.6), BRAF/MEK-inhibitor combination therapy is the standard-of-care 
for BRAF-mutant metastatic melanoma. 
While targeted therapies are effective in most patients (~65%) [116], unfortunately, the 
impressive initial tumour shrinkage is relatively short-lived and acquired resistance 
occurs in a high proportion of cases (58%) [117-119]. Another disadvantage of this type 
of therapy is that significant toxicities are associated with BRAF inhibitors [120] and 
combination therapies [121, 122]. Combination dabrafenib/trametinib regimens are 
associated with high fever whereas vemurafenib/cobimetinib combination therapy 
causes cutaneous and gastrointestinal adverse events [123]. Similarly, common adverse 
events with encorafenib/binimetinib included nausea, vomits, muscle spasms and 
altered liver function [124]. 
Immunotherapy 
Immunotherapy aims to strengthen the anti-tumour immune response in patients with 
stages III or IV malignant melanoma. In 2011, the FDA approved the use of immune 
checkpoint inhibitor, ipilimumab for unresectable metastatic melanoma. This antibody 
binds to the cytotoxic T-lymphocyte antigen 4 (CTLA-4) on tumour cells and blocks its 
activity, allowing immune cells to target the melanoma cells. Unfortunately, the patient 
response rate is low (11.9%) and immune-related adverse effects, such as, dermatitis, 
diarrhoea and colitis, are severe and common [125]. 
Alternate immune attenuating checkpoints have been identified including the interaction 
between programmed death-1 factor (PD-1) with its ligand (PD-L1) on diverse cells, such 
as, antigen-presenting cells and tumour cells. This interaction is now routinely targeted 
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for the treatment of metastatic melanoma [110, 126]. Pembrolizumab and nivolumab are 
anti-PD-1 antibodies approved by the FDA for the treatment of advanced melanoma in 
BRAF negative melanomas [127, 128] or as a second-line therapy in patients that acquire 
resistance to BRAF inhibitors. Although the toxicities associated with these agents are 
severe, the frequency is lower than for ipilimumab. The objective response rates of 
melanoma patients to nivolumab, and pembrolizumab are 43.7% and 33.7% respectively 
[109, 129]. 
Although immunotherapies have shown long-lasting effects in a moderate proportion of 
metastatic melanoma patients, approximately one-fourth/one-third of the patients will 
eventually relapse after showing initially an objective response to treatment [130]. 
Currently, much effort is placed on developing different therapeutical strategies to 
transform immunologically “cold” tumours into “hot” tumours. These approaches involve 
combination therapies [109, 131, 132] and the use of targeted therapy plus 
immunotherapy. Clinical trials of combination immune therapies [133-136] which 
compare the efficacy of single-agent nivolumab or ipilimumab versus ipilimumab plus 
nivolumab demonstrate increased response rates and overall survival in the combination 
therapy (Figure 1.6). 
The increase in overall survival offered by immunotherapy and targeted therapy 
generated considerable interest to investigate these therapeutic agents in the 
neoadjuvant and adjuvant settings. Neoadjuvant therapy would allow curative surgical 
resection in melanoma patients with locally advanced disease. The use of neoadjuvant 
therapy is currently an active field of research, especially for patients with stage III that 
are at high risk of relapse. Numerous completed and ongoing trials are investigating the 
use of immunotherapies in the neoadjuvant setting. 
Systemic immunotherapies have also shown a positive effect in stage III and IV post-
surgery patients as an adjuvant treatment. Recent studies have demonstrated that 
adjuvant ipilimumab following resection of stage III disease improves PFS and OS rates 
at 5 years versus placebo (65% and 54% respectively). 
However, in the ipilimumab cohort, grade 3 or 4 adverse events occurred in 41.6% of 
patients, together with 5 deaths (1.1%) [137]. Studies comparing ipilimumab with 
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nivolumab for resected stage III and IV disease, identified nivolumab as more effective 
and less toxic than ipilimumab [106]. However, further studies are needed to identify the 
best adjuvant therapy, as well as the dose and the duration of treatment that will benefit 
most patients. 
Figure 1.6. Summary of A) progression-free and B) overall survival by Kaplan–Meier analysis 
across clinical trials in patients with advanced-stage melanoma. Retrieved from Ugurel et al. 
[138]. 
Combinations of BRAFi and immunotherapy 
Since BRAF-targeted therapy is associated with favourable effects in the tumour 
microenvironment [139-141], it was hypothesised that multi-modality treatment 
approaches that combine targeted therapies and immunotherapies might be of clinical 
value. Clinical trials comprising targeted therapies together with immunotherapies are 
also now underway, to explore the safety of the triple-combination of BRAF, MEK, and 
Image is available https://pubmed.ncbi.nlm.nih.gov/28756137/
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PD-1 or PD-L1 inhibitors (CD-ON-MEDI4736-1161; KEYNOTE-022; COMBI-I; GP28384/ 
TRILOGY). Initial data suggests that this combination is well tolerated, and response rates 
are similar to those observed with BRAF-MEK inhibitor combinations [142-146]. Further 
investigations will provide a more extensive understanding of the clinical utility of these 
therapies and their long-term efficacies. 
Intratumoral Immunotherapy 
More recently, melanoma treatments may include T-VEC, a genetically modified herpes 
virus that replicates in carcinogenic cells when directly administrated into tumours. This 
oncolytic virus induces the production of granulocyte-macrophage colony-stimulating 
factor, improving the antigen presentation by macrophages, and enhancing a broader 
immune response to tumour antigens [147]. 
T-VEC is the most recent agent approved by the FDA for local treatment of advanced-
stage, unresectable cutaneous, subcutaneous, and nodal lesions in patients with 
recurrent melanoma after surgery. Preliminary data from clinical trials indicate that 
lower toxicities and higher response rates are observed in patients treated with T-VEC in 
combination with ipilimumab (~50%) [148] or pembrolizumab (~46%) [149]. Ongoing 
trials are now comparing T-VEC alone or in combination with checkpoint inhibitors in 
advanced melanoma [150]. 
1.2.8 Melanoma blood-based biomarkers 
Current therapeutic options for late stage melanoma disease are more effective in 
patients with a lower disease burden [151, 152]. The ability to identify melanoma at 
earlier stages or to recognise signs of disseminating disease prior to overt metastatic 
disease would be of significant clinical benefit. In addition, the rapidly evolving clinical 
landscape of melanoma therapy would be dramatically improved by the development of 
reliable and accurate biomarkers to provide accurate molecular classification and 
prognostication, and to monitor patient surveillance, during and/or post-treatment 
[153]. 
Currently, there are limited blood-based or tissue-specific biomarkers that are used for 
the clinical assessment of melanoma. One such marker routinely used to determine 
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prognosis in later disease stages is LDH, now incorporated into the TNM staging of 
melanoma [154]. However, the sensitivity of this marker is reduced during progression 
because it has a narrow dynamic range and its increase can be associated with non-
specific inflammatory conditions [155]. 
MicroRNAs (miRNAs) present in the blood of melanoma patients can discriminate 
between healthy individuals and cancer patients [156]. Moreover, miRNA 150-5P [156] 
and miRNA 206 [157] have been found to predict melanoma patients with shortened PFS. 
Melanoma exososomal proteins, such as tyrosinase-related protein 1 (TYRP1), 
tetraspanin CD63 and caveolin-1 have been found elevated in patients with advanced 
stage melanoma [158] and related to the development of resistance to treatment [159, 
160]. 
Circulating tumour cells (CTCs) have also been indicated as a prognostic marker for 
melanoma [161-164], with the presence of these cells in the blood correlates with poor 
prognosis and short survival despite systemic treatment [165-167]. Additionally, 
heterogeneous CTCs have been identified with distinct populations shown to respond 
differently to targeted and immune therapies [168-170]. 
Although the prognostic utility of novel melanoma biomarkers, such as miRNA, 
exosomes, and CTCs have been evaluated with promising results, none have been utilised 
in the clinic to date for melanoma. Therefore, the ability to measure disease burden and 
treatment responses is limited and there is a need for biomarkers that are sensitive or 
specific enough to be beneficial for early detection of melanoma and prediction of 
treatment response and, to monitor melanoma and assess therapeutic responses are 
required. 
1.3 Circulating tumour DNA (ctDNA) 
The presence of fragments of cell-free nucleic acids (cfDNA) in human blood was first 
described by Mandel and Métais in 1948 [171]. These cfDNA are short nucleic fragments 
(~166 bp) found in plasma, serum, urine, cerebrospinal fluid, pleural fluid, and saliva 
[172-174]. It is thought that cfDNA is released as a result of cell apoptosis and/or necrosis 
and may also be released by active secretion (Figure 1.7). 
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In healthy individuals, cfDNA is released from apoptotic and necrotic cells into the 
bloodstream to reach concentrations that range from 1 to 10 ng ml−1 in plasma [175-177]. 
However, these concentrations appear to be raised in patients with cancer, acute trauma, 
cerebral infarction or, as a result of exercise, transplantation and, infection, among other 
factors. In addition, cfDNA analysis provides “real-time” information about the mutations 
present in the tumour(s) since its half-life is between 15 minutes to 2.5 hours in 
circulation before it is cleared via degradation by the liver and kidney [178]. 
Figure 1.7. Analysis of cfDNA from the blood. cfDNA is released from cells undergoing apoptosis 
or necrosis. Retrieved from Crowley et al. [179]. 
Stroun and colleagues reported in 1989, that a proportion of cfDNA in the plasma of 
cancer patients originates from cancer cells [180]. However, only five years later, mutant 
KRAS sequences were first reported to be detected in the cfDNA of patients with 
pancreatic cancer, with the KRAS mutation matching that found in the patient’s tumour 
[181, 182], thus confirming that the mutations found in cfDNA are of tumour origin. Those 
tumour-specific DNA fragments were termed “circulating cell-free tumour DNA” (ctDNA) 
and are found to be shorter (134 - 144bp) than most cfDNA fragments [183]. 
Image is available https://doi.org/10.1038/nrclinonc.2013.110
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Circulating tumour DNA (ctDNA) is one marker with great potential to provide 
information pertaining to treatment response early during treatment. Plasma ctDNA is 
derived from tumour cells that undergo apoptosis and so molecular characterisation 
provides information that can guide therapeutic decisions. In addition, ctDNA levels are 
indicative of tumour burden in patients with advanced melanoma and may similarly 
indicate residual localised disease. 
Notably, at any one-time point, the blood of cancer patients contains ctDNA from multiple 
tumour sites, allowing faster, more accurate/complete analysis than that of individual 
tumour biopsies, which are from selected tumour sites. The short half-life of ctDNA [184] 
and the associated low risk of repeated collections enables the use of this liquid biopsy 
for detection of residual disease and to monitor cancer burden in response to a given 
therapy. In addition, genomic analysis of the ctDNA allows for early cancer detection and 
diagnosis (Figure 1.8). During the last decade, the development of more sensitive 
detection methods has allowed the study of this minimally invasive “liquid biopsy” for 
improved cancer management and monitoring. 
Figure 1.8. Applications of circulating tumour DNA analysis during the course of disease 
management. Retrieved from Wan et al. [185]. 
1.3.1 ctDNA detection methods 
The detection in ctDNA from the blood of melanoma patients poses a significant 
challenge. Sensitive methods are required to detect low amounts of ctDNA, quantify the 
number of mutant fragments of ctDNA, and discriminate between normal cfDNA and 
tumour ctDNA. The analysis of ctDNA can be separated into two approaches based on 
whether the objective is to monitor specific genes or mutations in a targeted approach or 
to examine all genes in an untargeted approach (Table 1.2). 
Image is available https://pubmed.ncbi.nlm.nih.gov/28233803/
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Table 1.2. Technologies for detecting circulating tumour DNA (ctDNA). Adapted from Elazezy et 
al. [186]. 
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SERS 0.1% 100% 5 ng 3 to 10 Known mutations Limited loci 
UltraSEEK 0.1% 100% 
9 pg-
4.2 ng 
Up to 40 Known mutations Limited loci 
 
Assays that target individual mutations can achieve high sensitivity using a relatively 
simple workflow. Allele-specific PCR methods have been applied for the detection of hot-
spot mutations in melanoma [187]. Similarly, a melanoma-specific panel was developed 
based on UltraSEEK technology [188]. Nevertheless, the most common methods to 
quantify plasma ctDNA are based on detection of single melanoma mutations by droplet 




Due to its high sensitivity and specificity, ddPCR has been recognised as one of the most 
accurate and reliable tools to examine genetic aberrations in a wide variety of cancers 
[191]. Studies assessing the validity of ctDNA as a biomarker of disease status in stage IV 
melanoma, show that the sensitivity of ddPCR appears to be similar to the BEAMing 
method, with ctDNA detection values ranging from 73% to 89% [12, 14, 17, 192, 193]. 
Since around 70% of melanomas harbour BRAF V600 or NRAS Q61 mutations, targeted 
approaches for ctDNA analysis are highly efficient in most melanoma cases. However, 
patients that are wild-type for BRAF and NRAS (approximately 30% overall) are more 
challenging to monitor since new, personalised targets have to be identified. While the 
sensitivity of ddPCR and BEAMing allow the detection of low frequency, specific 
mutations, they are most suited for investigating a small number of pre-identified targets. 
The development of technologies based on next-generation sequencing allows a broader 
study of the genome, enabling the monitoring of multiple tumour-specific mutations in a 
single assay. Targeted sequencing can be used to study small regions, such as individual 
exons, or a larger number of loci, expanding our ability to detect multiple genes of interest 
[194-197] (Table 1.2).  
1.3.2 ctDNA as a biomarker of disease status in metastatic cancers 
Various studies have shown that ctDNA levels correlate with tumour burden and disease 
stage in different cancer types [195, 198-201]. A study focused on comparing tumour 
volume with ctDNA levels in ovarian cancer, reported that ctDNA levels and disease 
volume were significantly correlated. In addition, the extent of the decrease in ctDNA 
levels after chemotherapy initiation was significantly associated with time to progression 
[202]. In patients with colorectal and breast cancer, detectable or increased ctDNA 
detection is a biomarker of worse survival compared with undetectable or decreasing 
ctDNA levels [195, 203]. 
Studies have also demonstrated that ctDNA can be used to monitor clonal evolution and 
identify mechanisms of resistance to treatment [7-10]. Serial ctDNA analysis in patients 
with colorectal cancer demonstrated the positive selection of KRAS mutant clones during 
EGFR blockade, and a later decline in the ctDNA levels from KRAS mutant clones upon the 
withdrawal of anti-EGFR therapy [204, 205]. In patients with NSCLC undergoing 
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treatment with EGFR inhibitors, resistance-conferring mutations emerged in plasma 
ctDNA prior to clinical progression determination [206, 207]. Studies in metastatic breast 
cancer comparing the sensitivity of ctDNA detection versus the widely used cancer 
antigen 15-3 biomarker showed ctDNA detection in 97%, in comparison with CA 15-3 
detection in only 78% of 30 women with metastatic breast cancer [195]. Similar results 
were found in colon cancer, where ctDNA anticipated tumour recurrence earlier than the 
carcinoembryonic antigen biomarker [208]. 
Taken together, this evidence led the FDA and the EMA to approve the use of ctDNA 
analysis in non-small cell lung cancer (NSCLC), to detect the tyrosine kinase resistant 
clone EGFR p.T790M mutation allowing the early identification of patients that will 
benefit from second-line drugs [11]. Current FDA and EMA recommendations for the use 
of ctDNA in NSCLC, state that, if liquid biopsies are performed in advance of a tumour 
biopsy, ctDNA detection may abrogate the need for tissue biopsy, but if ctDNA analysis is 
negative, a tissue biopsy may still provide valuable genomic information. In addition, 
ctDNA analysis has now been included in numerous clinical trials, shortening the gap 
between research and clinical practice. 
1.3.3 ctDNA as a biomarker for melanoma 
ctDNA as a prognostic biomarker 
The potential clinical validity of ctDNA for melanoma management has been addressed 
in previous studies. In particular, baseline ctDNA levels have been shown to significantly 
correlate with response to therapy [13, 209, 210], and were significantly associated with 
overall response rate (ORR) and PFS in melanoma patients undergoing targeted therapy 
[12, 15, 187, 193]. Ongoing clinical trials show that high basal levels of circulating BRAF 
V600E correlated with lower ORR and lower PFS to targeted therapy [12, 15]. These 
studies indicate that elevated ctDNA levels are a valid predictor of poor clinical outcome. 
Various studies have evaluated the prognostic value of ctDNA in melanoma management. 
Baseline ctDNA levels have been shown to significantly correlate with response to 
therapy and survival outcomes in melanoma patients receiving targeted therapy [12, 15, 
187, 193, 211]. A low baseline ctDNA level has been previously associated with long PFS 
in melanoma patients treated with immunotherapies [14, 212] and was found to 
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correlate with response to treatment [213-216]. In contrast, Lee et al. showed that a 
decline in ctDNA during treatment, but not low baseline levels, predicted longer PFS and 
OS [217]. Moreover, decreasing or undetectable ctDNA levels can distinguish between 
pseudoprogression or definite disease progression [218]. 
ctDNA as an indicator of treatment response 
Similarly, in melanoma, multiple studies have shown evidence of a significant correlation 
between ctDNA levels and tumour burden [14, 16, 193]. Since ctDNA is tumour specific 
and can expand over a dynamic range, it appears to be a more accurate blood-based 
biomarker than the currently used LDH marker for defining patient tumour status [13]. 
Tsao and colleagues demonstrated that ctDNA levels correlate with tumour burden as 
assessed by radiological scans in patients treated with immunotherapies [219]. 
Furthermore, a close correlation (p<0.001), between ctDNA levels per mL of plasma and 
metabolic tumour burden (MTB) (FDG uptake by the tumour assessed by PET/CT [16, 
220]) has been identified. Interestingly, PET/CT remains more sensitive than ctDNA 
analysis at this stage, since ctDNA was not detectable in patients with an MTB value of 
less than 10, defining the limit of detection of ctDNA to date [221]. On the other hand, an 
increase in ctDNA levels during or after treatment can indicate disease progression. 
Frequent ctDNA analysis may lead to early detection of disease progression [14]. 
The surveillance of patients after receiving treatment is another potential clinical 
application of ctDNA. For patients who have achieved a complete response, ctDNA levels 
can be analysed to determine if the cessation of treatment is warranted. Conversely, for 
patients that have ceased treatment, monitoring of ctDNA levels, can help identify the 
emergence of recurrence. 
In regards to early-stage patients, a study in early-stage colorectal cancer involving 230 
patients indicated that recurrence-free survival at 3 years was 0% for the patients that 
had ctDNA-positive results at first follow-up after surgical resection, and was 90% for 
patients with undetectable ctDNA [222]. Similarly, in an early study of 55 breast cancer 
patients, ctDNA detection at first follow-up also indicated poor prognosis [223]. Thus, the 
detection of ctDNA following surgery or treatment with curative intent may signal the 
presence of minimal residual disease (MRD) even in the absence of any other clinical 
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evidence of disease. This has not been fully interrogated for melanoma. Further studies 
are required to elucidate whether ctDNA detection may indicate the presence of residual 
tumour mass that was not eradicated by standard treatment. 
ctDNA analysis for comprehensive mutational profile 
In melanoma tumours, clonal heterogeneity plays an important role in patient response 
to treatment and the development of resistance to treatment. While targeted therapies 
can efficiently target dominant clones, they can also drive an increase in the population 
of resistant clones. For example, recent studies have shown that ctDNA can be used to 
monitor the emergence of mutations responsible for driving acquired resistance to BRAF 
and/or MEK inhibitors in melanoma, such as, the NRAS (Q61K), MAP2K1 (E203K), PTEN, 
AKT1 [13, 14, 16]. These mutations appear in the ctDNA of patients that developed 
acquired resistance to BRAF inhibitor treatments, in some cases earlier than radiological 
evidence of disease resistance [224, 225]. In addition, low-coverage WGS and WES 
analyses of ctDNA identified BRAF amplification as a potential mechanism of resistance 
to MAPK inhibitors [16]. Therefore, monitoring BRAF V600 and NRAS (Q61K/R) ctDNA 
levels together with other mutations related to acquired resistance will aid in identifying 
when resistance emerges, allowing earlier transition to second-line treatment that leads 
to increased response rates and improved patient outcomes [226]. 
Overall, ctDNA appears to be a clinically valid biomarker with great potential to inform 
clinical decisions in melanoma. The ability to reflect tumour burden and clonal evolution 
makes it a reliable biomarker for disease monitoring and prediction of response to 
treatment. However, important limitations need to be addressed to define the real clinical 
utility of ctDNA as a melanoma-specific biomarker. 
Firstly, most ctDNA studies thus far have only analysed BRAF or NRAS mutant cases, 
which represent approximately 70% of patients. These studies have remarked on the 
high fidelity of BRAF mutant ctDNA to reflect disease burden and tumour status of 
patients prior to and during treatment [12-14, 210, 227]. However, there is a need to 
ascertain the detection rate and kinetics of other common mutations found in melanoma 
to determine whether they can be effectively used for patient surveillance during and 
post-treatment of BRAF wild-type patients. 
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Secondly, the improvement in the clinical management of melanoma and proactive 
approach to surveillance by imaging scans means that an increasingly number of patients 
are provided BRAF inhibitors and immunotherapy at the early signs of metastatic disease. 
Thus, there is now an increase in melanoma patients with low disease burden receiving 
therapy. It is therefore imperative to improve the detection rate of ctDNA in melanoma 
and to ascertain its utility as a liquid biopsy as a suitable alternative for tissue biopsy for 
mutational analysis. 
Thirdly, limited studies have evaluated the predictive value of baseline ctDNA in patients 
treated with immunotherapy. Hence, studies that clarify the ability of ctDNA to predict 
survival in patients treated with immunotherapies are required, particularly examining 
prior treatment regimens and mutation status. 
Lastly, while previous studies have demonstrated the efficiency of ctDNA to indicate 
disease progression earlier than conventional imaging, such comparisons need to be 
conducted in a large cohort of patients. Cross-sectional studies aimed at comparing the 
efficiency of ctDNA to indicate treatment response or failure and disease progression 
against conventional clinical standards will inform whether this liquid biopsy is a suitable 





1.4 Rationale for this study 
There is a clear need for novel diagnostic and molecular tools in oncology, particularly in 
melanoma. Australia has one of the highest melanoma incidences world-wide and the 
annual estimated treatment cost for all new melanoma cases in Australia has risen to 
AU$201 million [228]. Numerous health resources are used in melanoma management, 
including doctor consultations, tissue biopsies, tumour surgeries, imaging examinations, 
targeted treatments, radiation therapies and chemotherapies. Currently, targeted 
therapies and immunotherapies are within the standard treatment regimens for 
metastatic melanoma in Australia and several other countries [229]. However, these 
novel therapies are exceptionally expensive [230, 231] and can have severe side effects. 
Therefore, non-invasive and cost-effective biomarkers are required for the early 
detection of therapeutic response and disease progression to aid with timely treatment 
adjustments. 
In recent years, ctDNA has emerged as a clinically relevant oncological biomarker for 
tumour genotyping, prognostication and disease monitoring, as demonstrated by the 
multiple studies in breast, lung and ovarian cancers [192, 232, 233]. In melanoma, ctDNA 
levels before therapy initiation of BRAF inhibitor or immunotherapies, correlated with 
tumour burden and were associated with ORR and PFS [12, 15, 187, 193]. Changes in 
plasma ctDNA level during treatment was indicative of either response (decreased) or 
treatment failure (maintained or increased), even prior to clinically identifiable 
progressive disease in some cases [14, 16]. Furthermore, this blood-based biomarker is 
isolated from blood using minimally invasive procedures and can be analysed using 
relatively low-cost tests, such as ddPCR assays. Thus, ctDNA may provide a holistic, cost-
effective, and highly specific analysis and tracking of each patient’s disease status for 
improved clinical management of melanoma. 
Although tumour tissue biopsy remains the gold standard in diagnosis and mutational 
analysis for clinical management of melanoma, the acquisition of tumour tissue is often 
limited by the need for highly invasive surgical procedures and/or inaccessible tumour 
locations. A significant concordance between the mutational profile obtained from tissue 
and plasma biopsies has been previously reported [15, 234]. These studies highlight the 
ability of ctDNA to capture the genetic heterogeneity of melanoma tumours and its 
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potential inclusion in the clinical setting as an alternative to tumour genotyping. It is, 
therefore, important to evaluate the clinical validity of ctDNA for the detection of BRAF 
V600 mutant patients that will be eligible for BRAF/MEK inhibitor therapy. 
The development of new therapies for melanoma has triggered the urgent need to 
investigate biomarkers that allow efficient monitoring of patient disease. Baseline ctDNA 
levels and subsequent decline with treatment have been indicated as an early predictor 
of tumour response and clinical benefit [14, 193, 217]. In melanoma, BRAF mutant ctDNA 
is a robust biomarker for disease burden and tumour status of patients before and during 
targeted treatment [14, 16, 234, 235]. However, many patients receiving first-line 
immunotherapy, especially in Australia, are BRAF WT and may carry NRAS or other 
mutations. Therefore, further studies are needed to evaluate the prognostic and 
predictive value of early changes in ctDNA levels to inform therapeutic outcomes in BRAF 
as well as in non-BRAF metastatic melanoma patients receiving systemic therapies. 
Studies have suggested that ctDNA can serve as an indicator of treatment failure prior to 
clinically identifiable progressive disease, providing a lead time that may be important 
for effective subsequent treatments [14, 16]. However, very few studies [224, 225] have 
evaluated the efficacy of ctDNA to identify disease progression in a large cohort of 
melanoma patients and compare it to medical imaging, the current gold standard for 
disease monitoring. 
In conclusion, the overarching aim of this thesis is to evaluate the clinical validity of 
ctDNA within specific contexts of use for the management of metastatic melanoma. The 
result of these studies provides valuable information to aid the implementation of this 
biomarker in the clinic, ultimately improving clinical outcomes of melanoma patients.  
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1.4.1 Hypothesis and aims 
Hypothesis: Analysis of plasma ctDNA can aid treatment selection, disease monitoring and 
surveillance of metastatic melanoma patients. 
Aim 1. To determine the detection rate of BRAF mutations in plasma ctDNA and compare 
the efficacy of ctDNA as a medium for tumour genotyping relative to current 
clinical standards, including a cost analysis. 
Aim 2. To evaluate the ability of pre-treatment ctDNA levels to provide prognostic 
information in different treatment types and lines of therapies. 
Aim 3. To investigate how changes in ctDNA levels early during treatment correlate with 
response. 
Aim 4. To examine the validity of ctDNA to inform of disease progression in comparison 
to conventional clinical imaging. 
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We evaluated the predictive value of pre-treatment ctDNA to inform therapeutic 
outcomes in metastatic melanoma patients relative to type and line of treatment. 
Plasma ctDNA was quantified in 125 samples collected from 110 patients prior to 
commencing treatment with immune checkpoint inhibitors (ICI), as first- (N=32) or 
second-line (N=27) regimens, or prior to commencing first-line BRAF/MEK inhibitors 
therapy (N=66). An external validation cohort included 128 patients commencing ICI 
therapies in the first- (N=77) or second-line (N=51) settings. 
In the discovery cohort, low ctDNA (≤20 copies/mL) prior to commencing therapy 
predicted longer progression-free survival (PFS) in patients treated with first-line ICIs 
(Hazard Ratio (HR) 0.20, 95% Confidence Interval (CI) 0.07-0.53, P<0.0001), but not in 
the second-line setting. An independent cohort validated that ctDNA is predictive of PFS 
in the first-line setting (HR 0.42, 95% CI 0.22-0.83, P=0.006), but not in the second-line 
ICI setting. Moreover, ctDNA prior to commencing ICI treatment was not predictive of PFS 
for patients pre-treated with BRAF/MEK inhibitors in either the discovery or validation 
cohorts. Reduced PFS and overall survival were observed in patients with high ctDNA 
receiving anti-PD-1 monotherapy, relative to those treated with combination anti-CTLA-
4/anti-PD-1 inhibitors. 
Pre-treatment ctDNA is a reliable indicator of patient outcome in the first-line ICI 
treatment setting but not in the second-line ICI setting, especially in patients pre-treated 
with BRAF/MEK inhibitors. Preliminary evidence indicated that treatment-naïve patients 
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Metastatic melanoma is an aggressive type of skin cancer and responsible for most skin 
cancer-related deaths [293, 294]. In the last decade, the emergence of targeted therapy 
and immune-checkpoint inhibitor/s (ICI/s) has significantly changed the clinical 
management and outcome of melanoma patients [138, 295]. Current treatment options 
for unresectable stage III and stage IV disease [296] include BRAF targeted therapies for 
patients that have BRAF mutant melanomas, and ICIs with anti-PD-1 alone or in 
combination with anti-CTLA-4. However, durable response is only seen in a minority of 
patients, and the optimal sequencing of therapies and the selection of the most effective 
first-line therapy, remain controversial [297, 298]. The CheckMate 067 trial 
demonstrated that the combination ipilimumab and nivolumab resulted in superior long-
term survival outcomes compared to either nivolumab or ipilimumab monotherapy, with 
a 5-year overall survival of 52% [136]. However, in addition to being a more costly 
regimen [299], patients treated with combination therapy experienced more grade 3 or 
4 treatment-related adverse events relative to those treated with nivolumab or 
ipilimumab alone [299]. Thus, there is a need to better stratify patients who will require 
upfront combination therapy from those who may derive a similar benefit from anti-PD-
1 monotherapy. 
The potential clinical utility of ctDNA for melanoma management has been demonstrated 
in multiple studies. Elevated baseline ctDNA levels have been shown to significantly 
correlate with low overall response rate (ORR) and short progression-free survival (PFS) 
in melanoma patients receiving targeted therapy [12, 15, 187, 193]. However, there is a 
paucity of studies evaluating the predictive value of baseline ctDNA in patients treated 
with immunotherapy. Low baseline ctDNA level has been previously associated with long 
PFS in melanoma patients treated with ICI [14] and was found to correlate with tumour 
shrinkage on radiology [213]. In contrast, Lee et al. showed that a decline in ctDNA during 
treatment, but not low baseline levels, predicted longer PFS and OS [217]. Thus, more 
studies are needed to clarify and further refine the predictive value of ctDNA in patients 
treated with immunotherapies, particularly taking into consideration the line of therapy, 
prior treatment regimens and mutation status. 
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In this study, we analysed a prospective cohort of melanoma patients receiving systemic 
therapies, including a large proportion of BRAF wild-type (WT) cases. We compared the 
predictive value of pre-treatment ctDNA levels to inform survival outcomes in metastatic 
melanoma patients receiving first-line or second-line systemic ICI. Our observations were 
validated using published datasets from two independent cohort studies [16, 217, 218, 
300]. 
4.3 Materials and methods 
4.3.1 Discovery cohort 
We analysed a total of 125 baseline plasma samples collected prior to commencing 
systemic therapy from 110 patients with unresectable stage IV cutaneous melanoma 
enrolled in the study between 2013-2018 at Sir Charles Gairdner Hospital (SCGH) and 
Fiona Stanley Hospital (FSH) in Perth, Western Australia. Patients’ characteristics are 
presented in Figure 4.1 and Table 4.1. A subset of 15 patients were considered as baseline 
for their first- and second-line therapy. This study received approval from the Human 
Research Ethics Committee of Edith Cowan University (No. 11543 and No. 18957) and Sir 
Charles Gairdner Hospital (No. 2013-246). 
Figure 4.1. Study cohorts. Flow charts of the samples included in the analyses, which is 
comprised of 125 patients treated with first- or second-line ICI and first-line targeted therapy 
from the discovery cohort and 128 validation samples from two independent sites. *Samples 






Table 4.1. Clinical characteristics at baseline of the melanoma patients included in the study. 
 Discovery Cohort  Validation Cohort 
 1st line 
ICI 
2nd line ICI 
1st line 
TT 
 1st line ICI 2nd line ICI 
Variable N=32 (%) N=27 (%) N=66 (%)  N=77 (%) N=51 (%) 
Age       
≤65 12 (38) 14 (52) 41 (62)  38 (49) 30 (59) 
>65 20 (62) 13 (48) 25 (38)  39 (51) 21 (41) 
Sex       
Female 7 (22) 7 (26) 24 (36)  25 (32) 20 (39) 
Male 25 (78) 20 (74) 42 (64)  52 (68) 31 (61) 
AJCC Stage/M Classification       
IIIc     1 (1) 2 (4) 
M1a 4 (13) 7 (26) 14 (21)  16 (21) 1 (2) 
M1b 6 (19) 1 (3) 6 (9)  18 (23) 9 (18) 
M1c 14 (43) 11 (41) 30 (46)  13 (17) 17 (33) 
M1d 8 (25) 8 (30) 16 (24)  29 (38) 22 (43) 
Brain only metastasis       
Yes 2 (6) 5 (19) 2 (3)  1 (1) 8 (16) 
No 30 (94) 22 (81) 64 (97)  76 (99) 43 (84) 
LDH levels       
Normal 8 (25) 10 (37) 29 (44)  55 (71) 35 (69) 
Elevated 6 (19) 9 (33) 19 (29)  19 (25) 16 (31) 
Not available 18 (56) 8 (30) 18 (27)  3 (4)  
Treatment       
ICI       
Nivolumab  1 (3)   8 (10) 13 (25) 
Pembrolizumab 22 (69) 17 (64)   29 (38) 26 (51) 
Ipilimumab/Nivolumab 10 (31) 9 (33)   15 (20) 8 (16) 
Ipilimumab/Pembrolizumab     25 (32) 4 (8) 
Targeted Therapies       
Vemurafenib   4 (6)    
Dabrafenib   1 (2)    
Dabrafenib/Trametinib   61 (92)    
Prior lines of therapy       
BRAF±MEK inhibitors       
Dabrafenib/Trametinib  19 (70)    34 (67) 
Encorafenib/Binimetinib      1 (2) 
Vemurafenib      1 (2) 
ICI       
Ipilimumab  6 (22)    14 (27) 
Pembrolizumab  2 (8)     
Ipilimumab/Nivolumab      1 (2) 
BRAF mutation status       
BRAF Mutant 2 (6) 21 (78) 66 (100)  35 (45) 38 (75) 
NRAS Mutant 17 (53) 1 (3)   31 (41) 11 (21) 
BRAF/NRAS WT 13 (41) 5 (19)   11 (14) 2 (4) 





Written informed consent was obtained from patients prior to sample collection and 
analysis. Patients were clinically monitored, and the median follow-up period was 95 
weeks (range: 16-257 weeks). 
4.3.2 Validation cohort 
We pooled data from two independent cohorts of 128 unresectable stage III (N=3) and 
stage IV melanoma (N=125) patients recruited from the Melanoma Institute Australia 
(NSW) affiliated hospitals and Peter MacCallum Cancer Centre (Victoria), as previously 
described by Lee et al. [217, 218, 300] and Wong et al. [16]. Additional details and patient 
characteristics are shown in Figure 4.1 and Table 4.1. Further comparison between the 
discovery and validation cohorts is presented in Table S4.1. 
4.3.3 Treatment response and disease progression assessment 
Radiological assessment of treatment response and disease progression was performed 
at two to three monthly intervals by computed tomography (CT) and/or 18F-labeled 
fluorodeoxyglucose positron emission tomography (FDG-PET) scans. Magnetic 
resonance imaging (MRI) of the brain was also used where indicated. PFS was defined as 
the time interval between the start of therapy and the date of first clinical or radiological 
progression. 
4.3.4 Plasma sample preparation and cfDNA extractions 
Pre-treatment blood samples were collected into EDTA vacutainer or Cell-Free DNA 
BCT® (Streck, La Vista, NE) tubes. Isolated plasma was stored at -80oC until extraction. 
Plasma cfDNA was isolated from 1-5 mL of plasma using QIAmp Circulating Nucleic Acid 
Kits (Qiagen, Hilden, Germany), as per the manufacturer’s instructions. The recovered 
cfDNA was freezer-stored until ctDNA quantification. 
4.3.6 ctDNA quantification 
For the discovery cohort, the mutation target for ctDNA analysis was selected based on 
the mutation reported in each patient’s molecular pathology result (BRAF mutant) or, if 
BRAF WT, obtained from next generation sequencing of tissue biopsy using a custom 
melanoma panel, as previously described by Calapre et al. [234]. Commercially available 
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and/or customised probes were used to analyse ctDNA by droplet digital PCR (ddPCR). 
To cover all patients, we used a total of twenty-two different hotspot sequence variants 
in 10 different genes (Table S4.2 and Table S4.3). Droplets were generated using an 
Automatic Droplet generator QX200 AutoDG (Bio-Rad) and analysed using the 
QuantaSoft analysis software version 1.7.4 (Bio-Rad). Amplifications were performed in 
40 µL reactions using previously described cycling conditions [14]. Quantification results 
were presented in copies of ctDNA per mL of plasma. 
A cutoff of 20 copies/mL was used for comparison of our analyses with the results from 
different cohorts analysed in three laboratories. This is the minimum ctDNA 
concentration that could be reliably detected given that ctDNA was isolated from 1-5 mL 
of plasma, eluted in 30-60 µL, an input of 5-8 µL in the ddPCR reaction and using different 
copies per mL of plasma (copies/mL) as threshold based on specific assays (Table S4.2) 
[16, 217, 218, 300]. We confirmed the suitability of this cutoff value through ROC curve 
analysis using the discovery cohort data for prediction of 6-month PFS (Figure S4.1). 
Patients with more than 20 copies/mL were defined as having a high ctDNA level, while 
patients ≤20 copies/mL were considered to have low ctDNA level. 
4.3.7 Statistics 
A comparison of the patients’ characteristics between the discovery and the validation 
cohorts was performed using a Chi-Square or two-sided Fisher´s exact test, with the 
frequencies, percentages and the P-values reported. Similarly, patient characteristics 
were compared by group using a Chi-Square or two-sided Fisher’s exact test, reporting 
their corresponding P-values. A ROC curve was calculated to determine the best cutoff 
value to dichotomise ctDNA concentration to predict 6-month PFS. Multiple ctDNA cutoffs 
were calculated by averaging two consecutive ctDNA values. These values were then used 
to calculate survival HRs and 95% CI for each ctDNA cutoff following a previously 
described analysis [301]. 
Median PFS was calculated using the Kaplan-Meier method, and survival curves 
statistical significance was determined using the log-rank and Gehan-Breslow-Wilcoxon 
test, when indicated, to stress the importance of early events. Univariate and multivariate 





cohort, the validation cohort and ICI monotherapy or combination cohort. All statistical 
analyses were performed using GraphPad Prism version 8 (GraphPad Software Inc.), 
SPSS version 25 (IBM) and R Studio (v.1.1.456). Results with P<0.05 were considered 
statistically significant. 
4.4 Results 
4.4.1 Patient characteristics 
The discovery cohort comprised of 125 plasma samples. Of these, 66 were from patients 
with BRAF mutant melanoma commencing first-line targeted therapy, and most patients 
received dabrafenib/trametinib (61/66, 92%; Figure 4.1 and Table 4.1). A total of 32 
patients were treated with first-line ICI monotherapy or in combination (22 anti-PD-1 
alone, 10 anti-CTLA-4 plus anti-PD-1 combination treatment) and 27 were treated with 
second-line ICI/s. Of the latter, 19 (70%) received a combination of BRAF±MEK inhibitors 
as first-line treatment, while 8 patients received ICI monotherapy as first line followed 
by combination ICI (Table 4.1 and Table S4.1). Overall, the discovery cohort included 2 
BRAF mutant patients in the first-line ICI group (2/32, 6%) and 21 in the second-line ICI 
group (21/27, 78%). 
4.4.2 Baseline ctDNA and progression-free survival 
Consistent with previous studies, for patients treated with first-line targeted therapy, low 
plasma ctDNA level at baseline was predictive of longer PFS (median: 57 vs 29 weeks, HR 
0.54, 95% CI 0.30-0.98, P=0.025; Figure S4.2). We then evaluated the predictive value of 
baseline ctDNA levels in patients receiving first- or second-line ICI in the discovery 
cohort. No statistically significant differences between clinical patients’ characteristics 
were associated with ctDNA levels (Fisher’s exact test, Table S4.4). However, patients 
with low ctDNA levels prior to first-line treatment initiation (N=18) had a significantly 
longer PFS, with undefined median, compared to patients with high levels of ctDNA 
(median PFS 8 weeks, HR 0.20, 95% CI 0.07-0.53, P<0.0001; Figure 4.2A). The predictive 
value of ctDNA was significant across multiple cutoff values (Figure S4.3A). Multivariate 
Cox regression analysis controlling for age, sex, tumour stage, brain metastases and BRAF 
status confirmed that low ctDNA level at baseline was an independent predictor of longer 






Figure 4.2. Kaplan-Meier curves for progression-free survival (PFS) of melanoma patients treated with ICI. Patients were stratified into those with 
low (green) or high (red) baseline ctDNA levels. Each graph denotes PFS outcomes in the discovery (A-C) or validation cohorts (D-F); for patients 
treated with ICI as first-line (A, D) or second-line treatment (B, E); or for BRAF mutant patients receiving ICI after failing first-line targeted therapy 





Analysis of patients receiving ICI as second-line (N=27) failed to demonstrate an 
association between low ctDNA and longer PFS (median PFS 31 vs 26 weeks, HR 1.05, 
95% CI 0.41-2.72, P=0.913; Figure 4.2B) using 20 copies/mL as cutoff or any other value 
(Figure S4.3B). Similar results were observed when removing 5 patients with intracranial 
disease only (Figure S4.4A). As 19/27 (70%) of patients receiving second-line ICI, had 
BRAF inhibitors (with or without MEK inhibitors) as first-line treatment, we evaluated 
the PFS outcome of this sub-group of patients. Low baseline ctDNA in patients 
commencing ICI as second-line after failing therapy with BRAF±MEK inhibitors was not 
a predictor of longer PFS (median: 30 vs 3 weeks, HR 0.59, 95% CI 0.16-2.24, P=0.356; 
Figure 4.2C and Figure S4.3C), contrary to the first-line ICI setting. Nevertheless, this 
observation was derived from a small cohort (14 vs. 5) patients. 
4.4.3 Validation cohort 
Two independent melanoma patient cohorts receiving ICI/s in the first- or second-line 
setting were combined and used to validate our findings (N=128). This validation cohort 
comprised 77 patients treated with first-line ICI (37 anti-PD-1 monotherapy, 40 anti-
CTLA-4 plus anti-PD-1 combination) and 51 patients treated with second-line ICI/s. Of 
these 51 patients, 36 (71%) were treated with first-line BRAF±MEK inhibitors (Table 
S4.1), while 14 (27%) were treated with ipilimumab and 1 (2%) was treated with 
ipilimumab plus nivolumab as first-line treatment. The cohort included 35 (35/77, 45%) 
BRAF mutant patients in the first-line ICI group and 38 (38/51, 75%) in the second-line 
ICI group. The validation cohort had a significantly higher number of BRAF mutant 
patients treated with first-line ICI than the discovery cohort (35/77, 45% vs 2/32, 6%, 
P<0.0001, respectively; Table S4.1). Similarly, there was a significantly higher number of 
patients treated with combination ICIs in the first-line setting than in the discovery 
cohort (P=0.048). No other statistical difference in patient characteristics was found 
between the validation and the discovery cohorts. 
4.4.4 Baseline ctDNA predictive value in the validation cohort 
Similar to the discovery cohort, patients with low baseline ctDNA levels prior to first-line 
ICI showed a significantly longer PFS than patients with high ctDNA levels (median PFS 
undefined vs 42 weeks, HR 0.42, 95% CI 0.22-0.83, P=0.006; Figure 4.2D). The predictive 
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value of ctDNA was significant across multiple cutoff values (Figure S4.3D). Multivariate 
Cox regression analysis controlling for age, sex, tumour stage, brain metastases, BRAF 
status and LDH confirmed that low ctDNA level at baseline prior to first-line ICI, was an 
independent predictor for longer PFS (HR 2.423, 95% CI 1.17-5.02, P=0.017; Table S4.6). 
Figure 4.3. Kaplan-Meier plots comparing survival of patients receiving first-line single-anti-PD-
1 and ICI combination. Patients were separated based on high (A-B, red) and low (C-D, green) 
baseline ctDNA levels, treated with anti-PD-1 alone (dashed line) or with combination anti-CTLA-
4 plus anti-PD-1 (solid line). Graphs represent progression-free survival (PFS; A and C) and 
overall survival (OS; B and D). Log-rank P-values, Hazard Ratio (HR) and 95% confidence 
intervals (CI) are indicated for each plot. *Represents Gehan-Breslow-Wilcoxon P-values. 
Similar to the discovery cohort, low ctDNA was not associated with longer PFS in the 
second-line setting in the validation cohort (median PFS 49 vs 13 weeks, HR 0.61, 95% CI 
0.30-1.25, P=0.143; Figure 4.2E) using 20 copies/mL or below as cutoff value (Figure 
S4.3E). Notably, within the group with low ctDNA levels in the second-line ICI setting, a 
significantly higher number of patients had metastases in brain-only compared to the 
group with high ctDNA levels (P=0.016; Table S4.7). When removing from the analysis 
cases with intracranial disease only, patients with high ctDNA levels had decreased PFS 





For BRAF mutant patients who received ICI after failing first-line targeted therapies 
(N=36), low baseline ctDNA level did not predict longer PFS in the validation cohort 
(median PFS 26 vs 14 weeks, HR 0.92, 95% CI 0.41-2.09, P=0.838; Figure 4.2F and Figure 
S4.3F), as observed in the discovery cohort. This result was maintained when removing 
from the analysis patients with intracranial disease only (median PFS 26 vs 14 weeks, HR 
0.70, 95% CI 0.27-1.78, P=0.431; Figure S4.4C). 
4.4.5 Survival analysis in patients with high ctDNA treated with combination or 
single agent ICI in the first-line setting 
Overall, ctDNA was found to be predictive of PFS in patients treated with first-line ICI. 
However, patients with high ctDNA levels in the validation cohort showed longer PFS 
compared to patients with similarly high baseline ctDNA levels in the discovery cohort (8 
vs 42 weeks, red lines in Figure 4.2A and Figure 4.2D). It is important to note that in the 
discovery cohort, only 29% (4/14) of patients with high ctDNA levels at baseline were 
treated with combination anti-CTLA-4 plus anti-PD-1 therapy, compared to 58% (19/33) 
of patients in the validation cohort (Table S4.4 and Table S4.7). 
To investigate whether the combination of ICIs is more effective in patients with high 
ctDNA, patients from both cohorts were combined and dichotomised according to 
whether they had high or low baseline ctDNA levels. Within these groups, survival 
outcomes were compared in patients who received single agent anti-PD-1 versus 
combination of ICIs. Comparison of patient characteristics revealed a larger proportion 
of BRAF mutant patients with low ctDNA levels received combination therapy (P=0.003; 
Table S4.8). 
Albeit not significant, a trend showing longer PFS was observed for patients with high 
baseline ctDNA treated with combination of ICIs when compared to those who received 
anti-PD-1 monotherapy (median: 42 vs 7.5 weeks, HR 1.79, 95% CI 0.90-3.53, P=0.081; 
Figure 4.3A). Similarly, patients treated with combination therapy showed longer OS 
(median: 186 vs 43 weeks, HR 1.91, 95% CI 0.87-4.21, P=0.104; Figure 4.3B). However, 
OS was significant when the Gehan-Breslow-Wilcoxon test was used (P=0.028), reflecting 
the difference in events occurring at the beginning of the curve. Patients with low ctDNA 
levels showed no differences in PFS or OS when treated with combination of ICIs versus 
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monotherapy (HR 1.97, 95% CI 0.87-4.47, P=0.124; Figure 4.3C and HR 1.74, 95%CI 0.63-
4.79, P=0.306; Figure 4.3D, respectively). However, none of the groups reached median 
PFS or OS, and a limited number of events were recorded within the follow up time. 
4.5 Discussion 
Studies investigating the ability of baseline ctDNA to predict treatment outcome in 
melanoma patients undergoing ICI are scarce, mainly including BRAF mutant melanomas 
and do not differentiate between treatment lines [14, 212, 217]. In this study, we showed 
that baseline ctDNA in metastatic melanoma patients receiving first-line ICI is a strong 
predictor of clinical outcome, as shown in both the discovery and validation cohorts. In 
contrast, the predictive value of ctDNA is lost in second-line ICI, particularly in patients 
failing first-line targeted therapy. Overall, our results redefine the context of use of ctDNA 
as a predictive biomarker in melanoma patients receiving immunotherapy, confining its 
utility to the first-line treatment setting. 
Currently, there is paucity of published data related to outcomes of patients who 
experience disease progression on BRAF inhibitor therapies and are treated with second-
line ICI. A recent retrospective study demonstrated that while ICI first-line efficacy 
appears comparable to trial populations, ICI treatment of BRAF mutant patients failing 
targeted therapy demonstrated a significantly lower response [302-304], and indeed, any 
drug therapy has lower efficacy in the second-line setting [305-307]. Consistent with 
these findings, our results demonstrate the limitation of ctDNA as a predictive biomarker 
in the second-line setting. Mason et al. found that BRAF mutant patients refractory to first-
line targeted therapy have a high proportion of brain metastases (47%) [302], a finding 
similar to that observed in the discovery and validation cohorts (37% and 58%, 
respectively). The brain is a common site of targeted therapy failure, often contributing 
to death [308]. Given that brain metastases have been reported to shed less ctDNA into 
the circulation [192, 300], the large proportion of disease progression within the brain, 
may contribute to the limited predictive value of ctDNA in this setting. In line with this, 
removal of patients with only intracranial metastases from the analysis improved the 
ctDNA predictive value in the validation cohort. However, ctDNA still failed to predict PFS 





The predictive significance of ctDNA levels prior to commencing targeted therapies has 
been previously demonstrated, with the absence of detectable ctDNA correlating with 
longer survival in large cohorts of melanoma patients [12, 15, 187, 193]. Similarly, we 
found that baseline ctDNA level was a strong predictor of clinical outcome in melanoma 
patients in the first-line targeted therapy setting, showing that high ctDNA level is 
associated with poorer clinical outcomes. 
The selection of first-line monotherapy over ICI combination is currently a complex 
decision and factors such as median tumour size, LDH levels, BRAF status, presence of 
brain metastases and comorbidities must be carefully considered [136, 309, 310]. We 
observed that in the validation cohort, more patients with high baseline ctDNA levels 
were treated with a combination of ICIs (19/33, 58%), while the patients in our discovery 
cohort were mainly treated with single agent ICI (10/14, 71%). In addition, the validation 
cohort had a significantly higher proportion of patients treated with a combination of 
ipilimumab and pembrolizumab as first-line therapy instead of ipilimumab plus 
nivolumab (P=0.006), as part of a clinical trial. Molecular and pre-clinical assessments of 
nivolumab and pembrolizumab suggest that these drugs could be interchanged and 
differences seen in clinical trials are likely related to patient populations rather than be 
drug-dependent [311]. Consequently, we showed that patients with high pre-treatment 
ctDNA levels tend to benefit from the combination of anti-CTLA-4 and anti-PD-1 as first-
line therapy. Although ctDNA level correlates significantly with tumour burden [16, 235], 
multivariate analyses in previous studies have shown ctDNA to be an independent 
predictor of survival [217, 235]. In this context, our results suggest that more aggressive 
treatment will be particularly beneficial to those patients with high ctDNA levels. 
Results from the Checkmate 067 study favours the use of ICI combination over anti-PD-1 
monotherapy, showing that patients treated with a combination of ICIs had increased 
both response (58% vs 45%) and 5-year overall survival rates (52% vs 44%) compared 
with those treated with anti-PD-1 monotherapy. These differences were accentuated in 
patients with BRAF mutations, with an increased 5-year survival rate in the combination 
group (60% vs 46%) [136]. In addition, it has been described that in patients with PD-L1 
negative tumours, the combination of PD-1 and CTLA-4 blockade was more effective than 
was either agent alone [109, 136]. Based on our results, elevated ctDNA may identify a 
group of melanoma patients that could benefit from ICI combination treatment. However, 
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our study was limited by the low number of patients with high ctDNA included in the 
survival analysis of single agent anti-PD-1 and combination of ICIs. Further prospective 
clinical trials are needed to confirm our observations and validate the use of ctDNA as a 
predictive biomarker for the treatment of melanoma patients. 
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ICI after Targeted Therapy 
P-valueDiscovery Validation Total Discovery Validation Total Discovery Validation Total 
Variable N=32 (%) N=77 (%) N=109 (%) N=27 (%) N=51 (%) N=78 (%) N=19 (%) N=36 (%) N=55 (%) 
Age 
≤65 12 (38) 38 (49) 50 (46) 
0.296 
14 (52) 30 (59) 44 (56) 
0.634 
8 (42) 21 (58) 29 (53) 
0.273 
>65 20 (62) 39 (51) 59 (54) 13 (48) 21 (41) 34 (44) 11 (58) 15 (42) 26 (47) 
Sex 
Female 7 (22) 25 (32) 32 (29) 
0.357 
7 (26) 20 (39) 27 (35) 
0.319 
5 (26) 15 (42) 20 (36) 
0.378 
Male 25 (78) 52 (68) 77 (71) 20 (74) 31 (61) 51 (65) 14 (74) 21 (58) 35 (64) 
AJCC Stage/M Classification 
IIIc/M1a/M1b 10 (32) 35 (45) 45 (41) 
0.203 
8 (30) 12 (24) 20 (26) 
0.593 
6 (32) 7 (19) 13 (24) 
0.336 
M1c/M1d 22 (68) 42 (55) 64 (59) 19 (70) 39 (76) 58 (74) 13 (68) 29 (81) 42 (76) 
Brain metastasis 
Yes 8 (25) 29 (38) 37 (34) 
0.268 
8 (30) 22 (43) 30 (38) 
0.758 
7 (37) 21 (58) 28 (51) 
0.163 
No 24 (75) 48 (62) 72 (66) 19 (70) 29 (57) 48 (62) 12 (63) 15 (42) 27 (49) 
Brain only metastasis 
Yes 2 (6) 1 (1) 3 (3) 
0.206 
5 (19) 8 (16) 13 (17) 
0.758 
5 (26) 8 (22) 13 (24) 
0.749 
No 30 (94) 76 (99) 106 (97) 22 (81) 43 (84) 65 (83) 14 (74) 28 (78) 42 (76) 
LDH levels 
Normal 8 (25) 55 (71) 63 (58) 
- 
10 (37) 35 (69) 45 (58) 
- 
6 (32) 24 (67) 30 (54) 
- Elevated 6 (19) 19 (25) 25 (23) 9 (33) 16 (31) 25 (32) 6 (32) 12 (33) 18 (33) 
N/A 18 (56) 3 (4) 21 (19) 8 (30) 8 (10) 7 (34) 7 (13) 
Treatment 
Nivolumab 8 (10) 8 (7) 
*0.048 
1 (3) 13 (25) 14 (18) 
*0.424 
8 (22) 8 (14) 
*0.999 
Pembrolizumab 22 (69) 29 (38) 51 (47) 17 (64) 26 (51) 43 (55) 12 (63) 16 (44) 28 (51) 
Ipilimumab/Nivolumab 10 (31) 15 (20) 25 (23) 9 (33) 8 (16) 17 (22) 7 (37) 5 (14) 12 (22) 
Ipilimumab/Pembrolizumab 25 (32) 25 (23) 4 (8) 4 (5) 7 (20) 7 (13) 
First-line therapy 
Vemurafenib 1 (2) 1 (1) 
- 
1 (3) 1 (2) 
- Encorafenib/Binimetinib 1 (2) 1 (1) 1 (3) 1 (2) 
Dabrafenib/Trametinib 19 (70) 34 (67) 53 (68) 19 (100) 34 (94) 53 (96) 
Ipilimumab 6 (22) 14 (27) 20 (26) 
Pembrolizumab 2 (8) 2 (3) 
Ipilimumab/Nivolumab 1 (2) 1 (1) 
BRAF mutation status 
BRAF V600 Mutant 2 (6) 35 (45) 37 (34) 
<0.0001 
21 (78) 38 (75) 59 (76) 
0.656 
19 (100) 36 (100) 55 (100) 
- 
BRAF V600 WT 30 (94) 42 (55) 72 (66) 6 (22) 13 (25) 19 (24) 





Table S4.2. Specificity of ddPCR assays. 
Assay 




BRAF V600E 0 22 0 
Life 
Technologies 
BRAF V600K 0 23 0 IDT 
BRAF V600R 0 24 0 IDT 
BRAF V600E2 1 12 1 IDT 
BRAF K601E 3 7 2 IDT 
BRAF L597Q 0 16 0 Bio-Rad 
NRAS Q61K 0 19 0 Bio-Rad 
NRAS Q61L 3 9 7 Bio-Rad 
NRAS Q61R 7 24 9 Bio-Rad 
NRAS G12D 4 6 3 Bio-Rad 
NRAS G13D 4 6 5 Bio-Rad 
TERT C228T/C250T Mult. 6 50 10 IDT 
DPH3 C8T 1 10 2 IDT 
GRM3 E538K 0 10 0 Bio-Rad 
GRM3 S491L 6 12 6 Bio-Rad 
FLT1 E011K 3 7 9 Bio-Rad 
KIT L576P 1 11 2 Bio-Rad 
NF1 P1851S 3 11 3 Bio-Rad 
RAC1 P29S 0 12 0 Bio-Rad 
TP53 R248W 2 14 2 Bio-Rad 
TP53 R248Q 6 8 2 Bio-Rad 
TP53 R158H 1 9 2 Bio-Rad 
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Table S4.3. Mutation status of the melanoma patients included in the study.
Discovery Cohort Validation Cohort 
1st line ICI 2nd line ICI 1st line TT 1st line ICI 
2nd line 
ICI 
Mutation status N=32 (%) N=27 (%) N=66 (%) N=77 (%) N=51 (%) 
BRAF 
BRAF V600E 13 (48) 50 (76) 24 (31) 27 (53) 
BRAF V600E2 1 (2) 
BRAF V600K 5 (18) 12 (18) 11 (14) 9 (17) 
BRAF V600R 1 (3) 2 (6) 3 (4) 2 (4) 
BRAF K601E 1 (3) 1 (4) 
BRAF L597Q 1 (3) 1 (1) 
BRAF L597S 1 (2) 
BRAF L597R 2 (3) 
BRAF G466E 1 (1) 
NRAS 
NRAS Q61K 8 (25) 1 (4) 12 (16) 4 (8) 
NRAS Q61L 4 (13) 5 (7) 2 (4) 
NRAS Q61R 3 (9) 13 (18) 4 (8) 
NRAS Q61H 1 (1) 1 (2) 
NRAS G12D 1 (3) 
NRAS G13D 1 (3) 
TERT 
TERT Mult. 1 (3) 
TERT C228T 1 (3) 1 (4) 
TERT C250T 1 (3) 1 (4) 
TERT -125CC>TT 1 (2) 
GRM3 
GRM3 E538K 1 (3) 
GRM3 S491L 1 (3) 
FLT1 
FLT1 E1011K 1 (3) 
KIT 
KIT L576P 2 (7) 1 (1) 
KIT K642E 4 (5) 
NF1 
NF1 P185S 1 (4) 
RAC1 
RAC1 P29S 2 (7) 1 (1) 
TP53 
TP53 R158H 1 (3) 
TP53 R248W 1 (3) 
TP53 R248Q 1 (4) 
TP53 Y220S 1 (1) 
DPH3 
DPH3 C8T 1 (4) 
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ICI after Targeted Therapy 
P-value Low ctDNA High ctDNA Total Low ctDNA High ctDNA Total Low ctDNA High ctDNA Total 
Variable N=18 (%) N=14 (%) N=32 (%) N=18 (%) N=9 (%) N=27 (%) N=14 (%) N=5 (%) N=19 (%) 
Age 
≤65 5 (28) 7 (50) 12 (38) 
0.277 
9 (50) 5 (56) 14 (52) 
0.999 
5 (36) 3 (60) 8 (42) 
0.603 
>65 13 (72) 7 (50) 20 (62) 9 (50) 4 (44) 13 (48) 9 (64) 2 (40) 11 (58) 
Sex 
Female 3 (17) 4 (29) 7 (22) 
0.669 
6 (33) 1 (12) 7 (26) 
0.363 
4 (29) 1 (20) 5 (26) 
0.999 
Male 15 (83) 10 (71) 25 (78) 12 (67) 8 (88) 20 (74) 10 (71) 4 (80) 14 (74) 
Melanoma Subtype 
Cutaneous 18 (100) 14 (100) 32 (100) - 18 (100) 9 (100) 27 (100) - 14 (100) 5 (100) 19 (100) - 
AJCC Stage/M Classification 
M1a/M1b 8 (44) 2 (14) 10 (32) 
0.124 
6 (33) 2 (24) 8 (30) 
0.676 
5 (36) 1 (20) 6 (32) 
0.999 
M1c/M1d 10 (56) 12 (86) 22 (68) 12 (67) 7 (76) 19 (70) 9 (64) 4 (80) 13 (68) 
ECOG 
0 11 (61) 4 (29) 15 (46) 
0.087 
11 (61) 3 (33) 14 (52) 
0.237 
8 (57) 2 (40) 10 (53) 
0.629 
1-3 7 (39) 10 (71) 17 (54) 7 (39) 6 (67) 13 (48) 6 (43) 3 (60) 9 (47) 
Brain metastasis 
Yes 5 (28) 3 (21) 8 (25) 
0.999 
6 (33) 2 (24) 8 (30) 
0.676 
6 (43) 1 (20) 7 (37) 
0.603 
No 13 (72) 11 (79) 24 (75) 12 (67) 7 (76) 19 (70) 8 (57) 4 (80) 12 (63) 
Brain only metastasis 
Yes 2 (11) 2 (6) 
0.492 
5 (28) 5 (19) 
0.136 
5 (36) 5 (26) 
0.257 
No 16 (89) 14 (100) 30 (94) 13 (72) 9 (100) 22 (81) 9 (64) 5 (100) 14 (74) 
LDH levels 
Normal 6 (33) 2 (14) 8 (25) 
- 
10 (55) 10 (37) 
- 
6 (43) 6 (32) 
- 
Elevated 1 (6) 5 (36) 6 (19) 3 (17) 6 (67) 9 (33) 3 (21) 3 (60) 6 (32) 
N/A 11 (61) 7 (50) 18 (56) 5 (28) 3 (33) 8 (30) 5 (36) 2 (40) 7 (34) 
Therapy 
Nivolumab 1 (6) 1 (3) 
*0.193Pembrolizumab 12 (67) 10 (71) 22 (69) 
0.999 
9 (50) 8 (89) 17 (64) 7 (50) 5 (100) 12 (63) 
0.106 
Ipilimumab/Nivolumab 6 (33) 4 (29) 10 (31) 8 (44) 1 (11) 9 (33) 7 (50) 7 (37) 
Timing of blood draw 
During 1st line Rx 8 (57) 2 (40) 10 (53) 
0.629 
After 1st line Rx 6 (43) 3 (60) 9 (47) 
BRAF mutation status 
BRAF V600 Mutant 1 (6) 1 (7) 2 (6) 
0.999 
15 (83) 6 (67) 21 (78) 
0.367 
14 (100) 5 (100) 19 (100) 
- 
BRAF V600 WT 17 (94) 13 (93) 30 (94) 3 (17) 3 (33) 6 (22) 





Table S4.5. Multivariate Cox proportional-hazards regression analysis for associations between 
ctDNA levels and PFS in patients receiving first-line ICI in the discovery cohort (N=32). 
 First-line ICIs 
Variables 
Univariate  Multivariate 
HR (95% CI) P-value 
 
HR (95% CI) P-value 
Age (≤65 vs. >65) 0.84 (0.34 - 2.09) 0.705 1.06 (0.39 - 2.85) 0.906 
Sex (female vs. male) 0.54 (0.20 - 1.42) 0.209  0.65 (0.23 - 1.81) 0.405 
AJCC Stage (M1a/b vs. M1c/d) 4.05 (1.17 - 14.02) 0.027  2.59 (0.67 - 10.12) 0.170 
Brain metastasis (no vs. yes) 2.31 (0.89 - 5.92) 0.082  1.84 (0.61 - 5.58) 0.283 
BRAF mutation status (mut vs. WT) 1.33 (0.18 - 10.02) 0.779  1.23 (0.14 - 10.47) 0.851 





Table S4.6. Multivariate Cox proportional-hazards regression analysis for associations between 
ctDNA levels and PFS in patients receiving first-line ICIs in the validation cohort (N=77). 
 First-line ICI 
Variables 
Univariate  Multivariate 
HR (95% CI) P-value 
 
HR (95% CI) P-value 
Age (≤65 vs. >65) 1.08 (0.57 - 2.03) 0.824 0.72 (0.33 - 1.59) 0.419 
Sex (female vs. male) 1.27 (0.63 - 2.55) 0.512  1.28 (0.58 - 2.81) 0.545 
AJCC Stage (IIIc/M1a/b vs. M1c/d) 1.44 (0.75 - 2.76) 0.272  1.58 (0.62 - 3.03) 0.341 
LDH levels (normal vs. elevated) 1.13 (0.53 – 2.41) 0.752  0.74 (0.32 – 1.71) 0.484 
Brain metastasis (no vs. yes) 1.24 (0.65 - 2.38) 0.514  0.94 (0.38 - 2.32) 0.889 
BRAF mutation status (mut vs. WT) 1.33 (0.69 - 2.54) 0.397  1.52 (0.72 - 3.23) 0.273 
ctDNA levels (low vs. high) 2.39 (1.26 - 4.55) 0.008  2.42 (1.17 - 5.02) 0.017 
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ICI after Targeted Therapy 
P-valueLow ctDNA High ctDNA Total Low ctDNA High   ctDNA Total Low ctDNA High ctDNA Total 
Variable N=44 (%) N=33 (%) N=77 (%) N=31 (%) N=20 (%) N=51 (%) N=23 (%) N=13 (%) N=36 (%) 
Age 
≤65 23 (51) 15 (45) 38 (49) 
0.647 
18 (58) 12 (60) 30 (59) 
0.999 
14 (61) 7 (54) 21 (58) 
0.736 
>65 21 (49) 18 (55) 39 (51) 13 (42) 8 (40) 21 (41) 9 (39) 6 (46) 15 (42) 
Sex 
Female 16 (36) 9 (27) 25 (32) 
0.466 
11 (35) 9 (45) 20 (39) 
0.565 
8 (35) 7 (54) 15 (42) 
0.310 
Male 28 (64) 24 (73) 52 (68) 20 (65) 11 (55) 31 (61) 15 (65) 6 (46) 21 (58) 
Melanoma Subtype 
Cutaneous 33 (76) 27 (82) 60 (78) 
- 
26 (84) 12 (60) 38 (75) 
- 
19 (82) 8 (62) 27 (74) 
- 
Acral 1 (2) 1 (3) 2 (3) 1 (3) 2 (10) 3 (6) 1 (5) 1 (7) 2 (6) 
Mucosal 1 (2) 1 (1) 
N/A 9 (20) 5 (15) 14 (18) 4 (13) 6 (30) 10 (19) 3 (13) 4 (31) 7 (20) 
AJCC Stage/M Classification 
IIIc/M1a/M1b 24 (55) 11 (33) 35 (45) 
0.071 
8 (26) 4 (20) 12 (24) 
0.743 
5 (22) 2 (15) 7 (19) 
0.999 
M1c/M1d 20 (45) 22 (67) 42 (55) 23 (74) 16 (80) 39 (76) 18 (78) 11 (85) 29 (81) 
ECOG 
0 26 (59) 16 (48) 42 (55) 
- 
16 (52) 4 (20) 20 (39) 
- 
10 (43) 1 (7) 11 (30) 
- 
1-3 11 (25) 14 (42) 25 (32) 9 (29) 10 (50) 19 (37) 8 (35) 7 (54) 15 (42) 
N/A 7 (16) 3 (10) 10 (13) 6 (19) 6 (30) 12 (24) 5 (22) 5 (39) 10 (28) 
Brain metastasis 
Yes 13 (30) 16 (48) 29 (38) 
0.102 
16 (52) 6 (30) 22 (43) 
0.157 
16 (70) 5 (38) 21 (58) 
0.089 
No 31 (70) 17 (52) 48 (62) 15 (48) 14 (70) 29 (57) 7 (30) 8 (62) 15 (42) 
Brain only metastasis 
Yes 1 (2) 1 (1) 
0.999 
8 (26) 8 (16) 
0.016 
8 (35) 8 (22) 
0.032 
No 43 (98) 33 (100) 76 (99) 23 (74) 20 (100) 43 (84) 15 (65) 13 (100) 28 (78) 
LDH levels 
Normal 38 (86) 17 (52) 55 (71) 
0.002 
24 (77) 11 (55) 35 (69) 
0.126 
18 (78) 6 (46) 24 (67) 
0.071 
Elevated 5 (11) 14 (42) 19 (25) 7 (23) 9 (45) 16 (31) 5 (22) 7 (54) 12 (33) 
N/A 1 (3) 2 (6) 3 (4) 
Therapy 
Nivolumab 3 (7) 5 (15) 8 (10) 
*0.491 
11 (35) 2 (10) 13 (25) 
*0.999 
7 (30) 1 (7) 8 (22) 
*0.720 
Pembrolizumab 20 (45) 9 (27) 29 (38) 13 (42) 13 (65) 26 (51) 9 (39) 7 (55) 16 (44) 
Ipilimumab/Nivolumab 6 (14) 9 (27) 15 (20) 4 (13) 4 (20) 8 (16) 4 (17) 1 (7) 5 (14) 
Ipilimumab/Pembrolizumab 15 (34) 10 (31) 25 (32) 3 (10) 1 (5) 4 (8) 3 (13) 4 (31) 7 (20) 
Timing of blood draw 
During 1st line Rx 6 (26) 3 (23) 9 (25) 
0.999 
After 1st line Rx 17 (74) 10 (77) 27 (75) 
BRAF mutation status 
BRAF V600 Mutant 20 (45) 15 (45) 35 (45) 
0.999 
24 (77) 14 (70) 38 (75) 
0.743 
23 (100) 13 (100) 36 (100) 
- 
BRAF V600 WT 24 (55) 18 (55) 42 (55) 7 (23) 6 (30) 13 (25) 





Table S4.8. Clinical characteristics at baseline of the melanoma patients included in Figure 4.3. 














Variable N=23 (%) N=24 (%) N=47 (%) N=27 (%) N=35 (%) N=62 (%) 
Age         
≤65 10 (43) 9 (37.5) 19 (40) 
0.770 
16 (59) 12 (34) 28 (45) 
0.721 
>65 13 (57) 15 (62.5) 28 (60) 11 (41) 23 (66) 34 (55) 
Sex         
Female 9 (39) 4 (17) 13 (28) 
0.110 
11 (41) 8 (23) 19 (31) 
0.169 
Male 14 (61) 20 (83) 34 (72) 16 (59) 27 (77) 43 (69) 
AJCC Stage/M Classification         
IIIc/M1a/M1b 7 (30) 6 (25) 13 (28) 
0.751 
13 (48) 19 (54) 32 (52) 
0.798 
M1c/M1d 16 (70) 18 (75) 34 (72) 14 (52) 16 (46) 30 (48) 
Brain metastasis         
Yes 10 (43) 9 (37.5) 19 (40) 
0.770 
10 (37) 8 (23) 18 (29) 
0.267 
No 13 (57) 15 (62.5) 28 (60) 17 (63) 27 (77) 44 (71) 
Brain only metastasis         
Yes    
- 
2 (7) 1 (3) 3 (5) 
0.575 
No 23 (100) 24 (100) 47 (100) 25 (93) 34 (97) 59 (95) 
LDH levels         
Normal 10 (43) 9 (38) 19 (40) 
- 
20 (74) 24 (69) 44 (71) 
- Elevated 12 (52) 7 (29) 19 (40) 4 (15) 2 (5) 6 (10) 
N/A 1 (5) 8 (33) 9 (20) 3 (11) 9 (26) 12 (19) 
BRAF mutation status         
BRAF V600 Mutant 11 (48) 5 (21) 16 (34) 
0.068 
15 (56) 6 (17) 21 (34) 
0.003 




Figure S4.1. ROC curve for ctDNA values in the first-line ICI for the discovery cohort. Analysis was performed using 6 months PFS as read out. The 
table indicates the sensitivity and the specificity associated to each cuttoff value. Highlighted in yellow and indicated by the arrow is the cuttoff values 
surrounding 20 copies per mL. Data was analysed and plotted using SPSS. 
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Figure S4.2. Baseline ctDNA levels relative to survival in first-line targeted therapy. Progression-
free survival (PFS) curve of melanoma patients with low and high ctDNA levels in the study 
cohort. Significant Cox regression P-values, Hazard Ratio (HR) and 95% confidence intervals (CI) 
are indicated in the plot. 
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Low ctDNA levels (N=37) 57 wks 26
High ctDNA levels (N=29) 29 wks 21
HR 0.54, 95% CI 0.30-0.98, P=0.025
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Figure S4.3. Cutoff optimisation by correlation with survival and ctDNA data. A-F, Relation between various ctDNA cutoffs, progression-free survival 
(PFS) and hazard ratio (HR) value, including 95% CI (grey shade). Each dot represents a possible ctDNA cutoff, and red dots denote non-predictive 
cutoffs (P>0.05), in the discovery (A-C) or validation cohorts (D-F). Each graph denotes survival HR for ctDNA cutoffs in patients treated with first-







Figure S4.4. Kaplan-Meier curves for progression-free survival (PFS) of second-line melanoma patients without intracranial disease only treated with 
ICI. Patients were stratified into those with low (green) or high (red) baseline ctDNA levels. Each graph denotes PFS outcomes in the discovery (A) or 
validation cohorts (B, C); for patients treated with ICI as second-line treatment (A, B); or for BRAF mutant patients receiving ICI after failing first-line 
targeted therapy (C). Log-rank P-values, Hazard Ratio (HR) and 95% confidence intervals (CI) are indicated for each plot. 
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5.1 Abstract 
In this study, we evaluated the predictive value of circulating tumour DNA (ctDNA) to 
inform therapeutic outcomes in metastatic melanoma patients receiving systemic 
therapies. We analysed 142 plasma samples from metastatic melanoma patients prior to 
commencement of systemic therapy: 70 were treated with BRAF/MEK inhibitors and 72 
with immunotherapies. Patient specific droplet digital polymerase chain reaction assays 
were designed for ctDNA detection. Plasma ctDNA was detected in 56% of patients prior 
to first-line anti-PD1 and/or anti-CTLA-4 treatment. The detection rate in the 
immunotherapy cohort was comparably lower than those with BRAF inhibitors (76%, 
P=0.0149). Decreasing ctDNA levels within 12 weeks of treatment was strongly 
concordant with treatment response (Cohen’s k=0.798, P<0.001) and predictive of longer 
progression free survival. Notably, a slower kinetic of ctDNA decline was observed in 
patients treated with immunotherapy compared to those on BRAF/MEK inhibitors. 
Whole exome sequencing of ctDNA was also conducted in 9 patients commencing anti-
PD-1 therapy to derive tumour mutational burden (TMB) and neoepitope load 
measurements. The results showed a trend of high TMB and neoepitope load in 
responders compared to non-responders. Overall, our data suggest that changes in ctDNA 
can serve as an early indicator of therapy outcomes in metastatic melanoma patients 
treated with systemic therapies and therefore may serve as a tool to guide treatment 
decisions. 
Keywords: circulating tumour DNA (ctDNA), melanoma, BRAF, response, targeted 






In recent years, improved knowledge of melanoma pathogenesis has led to the 
development of BRAF and MEK inhibitors that target tumours carrying BRAF oncogenic 
mutations, accounting for 40%-50% of all melanoma cases. Similarly, antibody-mediated 
blockade of immune checkpoints, particularly the cytotoxic T-lymphocyte-associated 
antigen-4 (CTLA-4) and the programmed cell-death protein 1 (PD-1), have markedly 
improved patient outcome in the last 5 years [116, 129, 152, 226, 312, 313]. However, a 
significant number of patients do not achieve sustained benefit from either targeted 
therapy or immunotherapy [129, 152, 226, 312, 313]. The most appropriate treatment 
sequence or therapy combinations that can maximise patient outcomes remains 
controversial [297, 314]. Predictive biomarkers of therapy response that can be assessed 
prior to initiation of treatment and early during therapy are critical to guide clinical 
management of metastatic melanoma. 
Analysis of tumour specific cell-free DNA (cfDNA) has been previously reported to be a 
reliable companion diagnostic biomarker in oncology [192, 275, 315, 316]. In melanoma, 
circulating tumour DNA (ctDNA) is a potential non-invasive alternative to tumour tissue 
biopsy for molecular profiling and longitudinal disease monitoring in the metastatic 
setting [317]. In addition, baseline ctDNA levels and subsequent decline with treatment 
have been indicated as an early predictor of tumour response and clinical benefit [14, 
193, 217]. To confirm the utility of ctDNA as a clinical biomarker, its ability to monitor 
and/or predict treatment response and clinical outcome requires further validation in a 
large cohort of melanoma patients, especially in those treated with immunotherapy. 
In melanoma, BRAF mutant ctDNA has been found to be a robust biomarker for disease 
burden and tumour status of patients prior to and during targeted treatment [14, 16, 234, 
235]. However, many patients receiving immunotherapy, are BRAF wild-type (WT). Thus, 
the detection rate of ctDNA and the value of ctDNA-based longitudinal monitoring in non-
BRAF melanoma patients need to be specifically assessed. 
Mutations, genetic rearrangements, insertions and deletions can encode novel, cancer-
specific neoantigens. Activation of T-cells is initiated by the recognition of novel peptides 
presented by human leukocyte antigens (HLA) complex. A high tumour mutational 





cancer (NSCLC) [318-322], melanoma [323, 324] and other cancers. Nonetheless, the 
predictive value of tissue-derived TMB for immunotherapy response needs further 
scrutiny and standardisation [325-327]. In this context, ctDNA has the potential to 
capture the mutational profile of all existing metastases [16]. However, whether this 
biomarker presents as an easily accessible and suitable tumour source for whole exome 
mutational load analysis and TMB measurement or neoepitope predictions in melanoma 
needs to be further defined. 
In this study, we aimed to ascertain the clinical utility of ctDNA to inform treatment 
response and survival in metastatic melanoma patients receiving systemic therapy. We 
compared ctDNA levels, detection rates, decay kinetics and predictive value between 
patients treated with immune checkpoint inhibitors and targeted therapies. We also 
explored whether ctDNA can be used for estimating tumour mutational and neoepitope 
load, to predict response to immune checkpoint inhibiting therapies. 
5.3 Materials and methods 
5.3.1 Patients 
We analysed a total of 142 plasma samples collected prior to commencing systemic 
therapy and 227 follow-up samples collected within 24 weeks of treatment initiation 
from 118 metastatic melanoma patients enrolled in the study between 2013-2018 at Sir 
Charles Gairdner Hospital (SCGH) and Fiona Stanley Hospital (FSH) in Perth, Western 
Australia. A subset of 24 patients were considered as baseline for their first- and second-
line therapy. Additional details of study design and patient inclusion or exclusion criteria 
in the different analyses can be found in Fig. S2. Approval by the Human Research Ethics 
Committee protocols from Edith Cowan University (No. 11543 and No. 18957) and Sir 
Charles Gairdner Hospital (No. 2013-246) was granted for this prospective study. Written 
informed consent was obtained from each subject prior to sample collection and analysis. 
Experiments were performed in accordance with institutional and national guidelines 
and regulations. Patients were clinically monitored with median follow-up duration of 
113 weeks (range: 28-286 weeks). Patient characteristics and clinical parameters are 





5.3.2 Treatment response and disease progression assessment 
Tumour disease responses were assessed radiologically by computed tomography (CT) 
and/or 18F-labeled fluorodeoxyglucose positron emission tomography (FDG-PET) scans 
at two to three monthly intervals. Patients were defined as responders if they had 
significant reduction in tumour size by the RECIST 1.1 on CT or FDG-PET scan as per the 
treating clinician, or presented a durable stable disease lasting more than 6 months. 
Progression-free survival (PFS) was defined as the time interval between the start of 
therapy and the date of first clinical progression. Overall survival (OS) was defined as the 
time interval between the start of therapy and death. Additionally, metastatic melanoma 
patients were stratified into four M-subcategories at baseline based on the location of the 
metastases [296]. 
5.3.3 Plasma samples preparation and cfDNA extractions 
Blood samples were collected prior to initiation of treatment and during subsequent 
follow-ups, into EDTA vacutainer or Cell-Free DNA BCT® (Streck, La Vista, NE) tubes. 
Within 24 hours of blood collection, plasma was separated by centrifugation at 300 g for 
20 minutes, followed by a second centrifugation at 4700 g for 10 minutes. All isolated 
plasma was stored at -80oC until extraction. Plasma cfDNA was isolated from 1-5 mL of 
plasma using QIAamp Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany) as per the 
manufacturer’s instructions. The recovered cfDNA was eluted in 40 µL AVE buffer 
(Qiagen, Hilden, Germany) and stored at -80oC until ctDNA quantification by droplet 
digital PCR (ddPCR). 
5.3.4 Tissue analysis 
Mutational profile of BRAF WT patients were identified from tissue biopsies as previously 
described by Calapre et al. [234] A custom targeted next generation sequencing panel of 
30 melanoma-associated genes (Illumina, San Diego, CA, USA) with 950 amplicons and an 
Illumina MiSeq instrument were used to identify mutational targets for ctDNA analysis in 
BRAF WT patients. Genomic variants were annotated using the Illumina Variant Studio 






5.3.5 Plasma ctDNA analysis 
Commercially available and/or customised probes were used to analyse ctDNA by ddPCR. 
Droplets were generated using an Automatic Droplet generator QX200 AutoDG (Bio-Rad, 
Hercules, CA). Amplifications were performed in 40µL reactions using cycling conditions 
previously described [14]. Twenty-six different mutation variants in 10 different genes 
were utilised. Customised primers and probes for TERT and DPH3 promoter mutation 
analyses were performed as previously reported by McEvoy et al. [257] and Calapre et al. 
[234], respectively. Limit of blank for the ctDNA assays was determined using normal 
plasma samples from at least 10 healthy controls. Levels of ctDNA were defined based on 
the level of false positive droplets as previously specified in Calapre et al. [234] or are 
detailed in Table S5.5. Samples yielding copies/mL of plasma equal or below the 
maximum false positive concentration were deemed ctDNA negative. 
5.3.6 Whole exome sequencing 
The concentrations of cfDNA used for WES ranged from 1 to 7 ng/uL of cfDNA, with ctDNA 
fraction >7% abundance. Whole exome sequencing (WES) was carried out using the 
Exome-seq Agilent V6 capture Kit (Agilent) by Novogene (Hong Kong, China). Sequence 
reads were aligned against human reference genome (hg19) using the Burrows-Wheeler 
aligner (BWA). Duplicate reads were marked with Picard Tools, reads were realigned 
against known indels and base qualities recalibrated using Genome Analysis Toolkit. As 
BWA assumes a unimodal distribution of fragment size, we adjusted the Proper Pair bit 
in read pairs following the approach in BWA but the fragment sizes were fitted against a 
mixture of two Gaussian models. 
Somatic variants were identified with an in-house tool using the statistical framework 
described by Li et al. [328] We used a model assuming diploid germline and calculated 
the phred-scaled likelihoods for possible genotypes. The tumour sample was modelled as 
a mixture of tumour and normal cell DNA and likelihoods were calculated for an array of 
different variant allele frequencies. The constrained log-likelihood ratio (CLR) was 
calculated and variants with CLR score of <70 were excluded from further analysis. 
Identified variants were further annotated using ANNOVAR. 
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5.3.7 Neoepitope Load Prediction 
To predict neoantigens formed by the somatic variants, we used pVACseq v4.0.9 [329] 
with epitope lengths 8-11 and NetMHCpan binding predictions [330]. 
5.3.8 Statistics 
Differences between ctDNA levels were estimated by unpaired t-test from the log 
transformed data. Paired t-test was used to evaluate difference between ctDNA levels at 
first and second-line treatment in BRAF mutant patients. Differences between the 
detection rates were assessed using two-sided Fisher’s exact test. PFS and OS were 
estimated using the Kaplan-Meier method, and differences were evaluated using Mantel-
Cox tests. Concordance between the clinical response and the ctDNA kinetics was 
calculated using the Cohen kappa measure with 95% CI from 1000 bias-adjusted and 
accelerated bootstrap (BCa) replications. Statistical difference between baseline and 
follow-up ctDNA levels from same individuals were assessed by the Poisson test, using 
the minimum and maximum values plus total droplet counts as analytical variables. 
Frequencies and percentages by group along with their corresponding P-values of the 
chi-squared test are reported in Table S5.1. Multivariate Cox regression analysis was 
performed for PFS and OS in Table S5.2. The unpaired two-tailed t-test was used to 
compare mutational and neoepitope load between patients that were responders or non-
responders to anti-PD-1 immunotherapy. Pearson correlation was used to determine 
correlation between mutational burden and neoepitope load. All statistical analyses were 
performed using R version 5.2, GraphPad Prism version 5 and SPSSv22.0. Results were 
considered statistically significant at P<0.05. 
5.4 Results 
5.4.1 Plasma ctDNA detection in melanoma patients commencing systemic therapy 
We first evaluated the rate of ctDNA detection in 142 plasma samples collected prior to 






Figure 5.1. ctDNA quantification in melanoma patients prior to commencing systemic therapy. 
(a) Plasma ctDNA levels (copies/mL of plasma) in melanoma samples (N=144), stratified by M 
status. M1d cases were further subdivided into those with extracranial (EC) and those with brain 
only metastases. Percentages denote the frequency of patients with detectable ctDNA. The 
geometric mean of ctDNA concentrations is indicated for each group by a dashed red line. 
Unpaired t-test P-values of the log-transformed ctDNA levels are indicated. (b) Dot plot diagram 
showing ctDNA at baseline in patients treated with immunotherapy (IT) and targeted therapy 
(TT). (c) ctDNA detection in patients with BRAF, NRAS, or BRAF/NRAS wild-type tumours 
commencing first-line treatment. (d) ctDNA detection at first-line and second-line treatment in 
BRAF mutant patients. Red dots represent patients with intracranial disease only at time of 
starting therapy. 
The ctDNA detection rate was 65% overall, but patients with one or more prominent 
visceral metastases (M1c), particularly in the liver, bone and lung, had significantly 
higher ctDNA detection rates when compared to those with M1a disease (P=0.002; Figure 
5.1A). Similarly, median ctDNA levels were significantly higher in M1c patients compared 
with M1a (P=0.001) or M1b (P=0.015). In addition, ctDNA levels in patients with M1d and 





Notably, none of the ten M1d patients with brain only metastases had detectable ctDNA 
(Figure 5.1A), indicating that ctDNA levels are influenced by the site of metastases. 
5.4.2 Baseline ctDNA detection prior systemic treatments 
We then compared the ctDNA detection rates in plasma collected prior to commencing 
treatment with immune checkpoint inhibitors or targeted agents. We observed reduced 
ctDNA concentrations and a significantly lower detection rate in patients receiving 
immunotherapy when compared to those receiving BRAFi±MEKi (56% vs 76%; P=0.014; 
Figure 5.1B). 
Due to the difference in ctDNA detection rates between the targeted therapy and 
immunotherapy groups, we evaluated whether the mutational target used for ctDNA 
analysis influenced these results. Comparison of the detection rate of ctDNA between 
mutational targets demonstrated no significant difference between ctDNA levels and 
detection rate (geometric mean: 19.2 copies/mL, 67/100, 67%) in patients with BRAF 
versus patients with other melanoma associated mutations (geometric mean: 13.7 
copies/mL, 26/42, 62%; Figure 5.1C). 
To determine if ctDNA levels are influenced by the line of therapy, we compared ctDNA 
levels in 21 BRAF mutant patients that received first-line targeted therapy and second-
line immunotherapy (Figure 5.1D). This sequence of treatment is commonly used for 
BRAF mutant melanoma in Australia. Despite not showing statistical significance, ctDNA 
detection rate was lower in patients commencing second-line treatment (81% vs 48%, 
P=0.100). This result is likely influenced by the effectiveness of regular radiological 
monitoring in identifying disease progression at low tumour burden. 
5.4.3 Longitudinal ctDNA monitoring for prediction of response 
We further investigated whether ctDNA positivity at baseline and early during the 
treatment course were correlated with treatment response. A total of 84 patients with 
longitudinal blood collections within 12 weeks of treatment were included and stratified 
according to treatment, that is, targeted therapy (N=47) vs immunotherapy (N=37), and 
divided into three groups depending on the ctDNA profile during the first 12 weeks of 





patients with undetectable ctDNA levels at baseline and during 12 weeks of therapy or 
non-significant ctDNA changes. Group B had detectable baseline ctDNA that became 
undetectable or significantly reduced during treatment and group C includes patients 
that were either ctDNA positive or negative at baseline with static or significantly 
increased levels during the first 12 weeks of therapy. Overall, groups A and B represented 
patients that showed a biological response, evidenced by undetectable or a significant 
reduction in ctDNA levels, and group C was comprised of patients that did not show a 
biological response, that is, detectable or non-significant reduction in ctDNA levels. 
An 86% observed agreement was found between the best clinical response within 6 
months from treatment initiation and the biological response offered by longitudinal 
ctDNA monitoring (72/84). Notably, a subset of seven patients without objective 
response or unequivocal disease progression, who were treated with either 
immunotherapies (N=3) or targeted therapies (N=4), had a biological response. A strong 
agreement was found between the biological and the clinical response (Figure 5.2B; 
κ=0.798, 95% CI 0.570 to 0.958, N=77, P<0.001), when these seven patients were 
excluded from the analysis. Discordance was observed in five patients (5/77, 6%), with 
three patients noted to have no detectable or significant decrease in ctDNA levels despite 
having clinical progression (PD) in subcutaneous lesions (Patient #170.2 and 755), lymph 
nodes (755), muscle (755 and 486) and brain (170.2). The PD lesions observed in patient 
170.2 were in the subcutaneous tissue and brain. By contrast, two patients (538 and 493) 
were found to have a clinical response to pembrolizumab and dabrafenib/trametinib, 
respectively, but no biological response was observed. 
We next compared the biological ctDNA response with longitudinal blood collection for a 
period of 24 weeks after starting treatment. In this cohort, most patients treated with 
anti-CTLA-4 and anti-CTLA-4/PD-1 did not show radiological response to therapy, and 
their ctDNA levels remained high (Figure S5.1A and S5.1B). By contrast, 17 of the 21 
(81%) patients receiving anti-PD-1 immunotherapy had a partial response (PR) or 
complete response (CR; Figure S5.1C). The clinical response rate in the targeted therapy 
cohort was also high (41/47, 87%) but a number of these patients (10/41, 24%) 
developed resistance and relapsed within the first 24 weeks of therapy, with 9 of them 






Figure 5.2. ctDNA levels early during treatment relative to clinical response. (a) Columns 
represent each patient, best clinical response, treatment type, and longitudinal quantitative 
ctDNA results. Patients treated with immunotherapy or targeted therapy were stratified into 
three profile groups: A=undetectable ctDNA at baseline and during treatment with biological 
response, B=detectable ctDNA at baseline that became undetectable during treatment or had a 
significant biological response and C=detectable/undetectable ctDNA at baseline that remained 
or became detectable during therapy without significant biological response. *Significant 
Biological Response. bPresence of only intracranial malignant disease at baseline or at PD. (b) 
Concordance between best clinical response at 6 months and biological ctDNA response within 
the 12 weeks of treatment. Patients categorised as clinically responders (PR/CR, N=61), patients 
with stable disease (SD, N=7), and patients with disease progression (PD, N=16) and, ctDNA 
responders (Group A and B; N=69) or non-responders (Group C; N=15) based on their biological 
ctDNA response over the first 12 weeks of treatment. Abbreviations: ND=Not detectable; 
NSD=Non-significant decrease. (c) Plasma ctDNA levels at baseline and follow-up in patients that 
responded to targeted therapy (N=26) and to immunotherapy (N=6). P-values of paired t-tests 
are indicated. The geometric mean ctDNA concentration is indicated for each group by a dashed 
red line. 
We analysed patients with objective clinical response that had detectable ctDNA at 
baseline and assessable follow-up samples. Within these groups, ctDNA dropped 
significantly by 3-6 weeks in the targeted therapy cohort (N=26, P<0.0001; Figure 5.2C). 
In contrast, most patients (67%) who responded to immunotherapy had detectable 
ctDNA levels at first follow-up and, only had the significant drop to undetectable levels 





5.4.4 Longitudinal ctDNA monitoring for prediction of survival 
We evaluated whether the ctDNA changes during the first 12 weeks of treatment (groups 
A, B or C) had prognostic value in patients treated with immunotherapy. For the survival 
analysis, patients receiving single-agent immunotherapy ipilimumab (N=8) were 
excluded due to their poor response rate and rapid transition into anti-PD-1, which may 
confound survival analysis. Clinical characteristics across the three groups were similar 
for age, sex, tumour stage, the prevalence of brain metastases and prior lines of treatment 
(Table S5.1). 
In patients receiving immunotherapy, groups A and B had significantly longer 
progression-free survival (PFS) and overall survival (OS) compared to group C (Figure 
5.3A and 5.3B). Median PFS for groups B and C was 73 and 5 weeks respectively, but was 
not reached for group A. The hazard ratio (HR) was 0.052 (95% CI=0.010 to 0.275, 
P=0.0005) for group A and 0.176 (95% CI=0.041 to 0.750, P=0.019) for group B when 
compared with group C. There was no statistical difference in the PFS of groups A and B 
(P>0.05). Median OS for group B and C were 150 and 24 weeks respectively but was not 
reached for group A (Figure 5.3B). The HR was 0.081 (95% CI=0.014 to 0.454, P=0.004) 
for group A and 0.190 (95% CI=0.395 to 0.922, P=0.039) for group B when compared 
with group C. There was no statistical difference in the OS of groups A and B (HR=0.705, 
95% CI=0.134 to 3.693, P>0.05). 
In a multivariate Cox regression model, ctDNA kinetics in group C was found to be an 
independent predictor of shorter PFS (HR=16.9, 95% CI=2.68 to 106.25, P=0.003) and OS 
(HR=22.48, 95% CI=2.75 to 183.69, P=0.004; Table S5.2). Notwithstanding the low 
number of samples in Group C (N=3), in patients treated with targeted therapy (Figure 
5.3C), group A had longer PFS when compared to compared to group B and C. Median PFS 
was 100, 39 and 5 weeks for group A, B and C, respectively. When compared with group 
A, the hazard HR was 0.458 (95% CI=0.215 to 0.977, P=0.043) for group B and 0.001 
(95% CI=4.548x10-5 to 0.027, P<0.0001) for group C. Despite the differences in the PFS 
between these groups, there was no difference between their median OS (Figure 5.3D, 
P>0.05). A multivariate Cox regression model, found that ctDNA kinetics in group B is an 
independent predictor of decreased PFS (HR=6.65, 95% CI=1.80 to 24.56, P=0.004) and 





samples in group C (N=3), these patients were excluded from the analysis. Interestingly, 
the prediction significance of ctDNA kinetics was attributed to the presence of patients 
with visceral plus brain and brain only patients in the analysis. When excluding group C 
patients from the multivariate analysis, ctDNA kinetics between groups was not found to 
be an independent predictor of PFS. 
5.4.5 Measuring mutational burden using ctDNA 
Plasma ctDNA analysis constitutes an attractive approach for real-time assessment of 
tumour mutational profile and alleviates caveats associated with tissue biopsies 
including tumour heterogeneity. Here, we determined the feasibility of quantifying 
mutational load in patient-derived cfDNA. We screened melanoma patients treated with 
anti-PD-1 inhibitor as a first- or second-line treatment, with a ctDNA fraction of more 
than 7% abundance by ddPCR. Nine patients were selected and dichotomised according 
to their best clinical response to therapy, with responders noted as having either a partial 
response, a complete response or prolonged stable disease. Non-responders are those 
without clinical or objective response and who had progressive disease within 6 months 
of treatment initiation. Clinical characteristics for these patients are described in Table 
S5.3. 
Mutational data were obtained from the nine patients, with the number of mutations 
ranging from 1-58 per Mb of DNA (Table 5.1). While patients that responded to anti-PD-
1 inhibitor had higher tumour mutational burden (TMB) compared to non-responders 
(mean: 21 vs 6 per Mb), the difference was not statistically significant (Figure 5.4A). 
Nonetheless, our results may be confounded by the small sample size analysed for TMB. 
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Figure 5.3. ctDNA levels early during treatment relative to survival. Progression free survival (PFS) and overall survival (OS) curves for patients 
treated with immunotherapy (a, b) or targeted therapy (c, d) stratified into the three previously detailed profile groups A, B and C. Cox regression P-





















MP0104 22 1362 236 
MP0105 2 131 32 
MP0201 4 432 86 
MP0302 58 1516 259 




MP0102 10 439 105 
MP0103 1 114 25 
MP0301 1 25 3 
MP0304 14 469 75 
As mutational burden alone did not explain clinical benefit from anti-PD-1 inhibitors, we 
hypothesised that the presence of specific tumour neoantigens might explain the varied 
dichotomised patients that are likely to benefit from this immunotherapy. To identify 
these neoepitopes, the HLA-I phenotype of each patient were identified and the 
bioinformatics pipeline for pVACSeq (https://github.com/griffithlab/pVAC-Seq) was 
used for neoepitope prediction. 
The number of predicted neoepitopes with a binding affinity of IC50<500nM ranged from 
25-1516 and was higher in responders (mean = 774) versus non-responders (mean = 
262) to immunotherapy (Figure 5.4B). The number of predicted neoepitopes with strong 
binding affinity (IC50<50nM) ranged from 3-259 and was similarly higher in responders 
compared to non-responders (mean = 134 vs 52, Figure 5.4C). However, the difference in 
the number of neoepitopes in these two groups was again not significant (P>0.05). 
Nonetheless, the number of neoepitopes correlated with the mutational burden (Figure 
5.4D-E). Overall, there was a trend that high neoepitope load was associated with 
response to anti-PD-1 treatments. Nevertheless, three of the five responders had 
neoepitope loads in the same range as the non-responders, indicating that at a singular 







Figure 5.4. ctDNA as a tumour source for mutational burden analysis. (a) Vertical scatter plot of the difference in the mutational burden (number of 
single-nucleotide variants (SNVs per Mb of DNA) in responders (green) and non-responders (red) to anti-PD-1 blockade. Graphs indicating the 
difference in the number of low - IC50<500nM (b) and high - IC50<50nM (c) affinity neoantigens in melanoma patients treated with immunotherapy. 






The prognostic value of ctDNA in melanoma patients has been previously shown by 
number of studies [13, 16, 187, 217, 331]. In this study, we found ctDNA detectability at 
baseline and during treatment course to be a strong predictor of clinical outcome. In 
particular, we showed that high levels of ctDNA at baseline and throughout the first 12 
weeks of treatment were indicative of poor survival outcome in melanoma patients 
receiving first-line immune checkpoint inhibitors as well as on those receiving targeted 
therapies. Moreover, patients with undetectable ctDNA at baseline, who remained ctDNA 
negative during treatment, have a longer time to progression irrespective of treatment. 
Notably, detectability of ctDNA and its resolution during treatment was also associated 
with good clinical outcome in patients treated with immunotherapy and targeted 
therapies. In addition, we describe for the first time a different ctDNA pattern of response 
in targeted therapy and in immunotherapy. 
Overall, our findings underscore the suitability of ctDNA as a prognostic biomarker for 
the currently available treatments of melanoma patients. Our findings indicate that 
ctDNA is most informative as an early indicator of clinical response. In fact, we found a 
significant concordance between baseline ctDNA levels and response to first-line 
immunotherapy and targeted therapy. The decline in ctDNA levels was found to be highly 
concordant with the radiological response to treatment, while increasing ctDNA levels 
was correlated with disease progression. These results are supported by previous 
findings [217] and further demonstrated the ability of ctDNA to accurately reflect disease 
status of patients, making it a valuable surrogate or companion biomarker for patient 
surveillance during treatment. 
Interestingly, we found a low response rate amidst patients treated with anti-PD-1 plus 
anti-CTLA-4, in contrast with that observed in clinical trials [109, 129]. The patients in 
our combined immunotherapy cohort had extensive brain metastases and/or 
widespread disease, which may have reduced the response rates. Moreover, very few 
patients in our cohort were treated with combined immunotherapy, and therefore the 
response rates observed here may not necessarily reflect that of previous studies. 
We also want to highlight the difference in the rate of ctDNA decay between patients 
treated with targeted therapy and immunotherapy. In this study, we observed a delayed 
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velocity of ctDNA decay in patients that respond to immunotherapy compared to patients 
undergoing targeted therapy. This data reflects the time interval necessary to unleash an 
immune response to cancer [332], which needs to be taken as an important consideration 
when monitoring response to different types of treatment through a liquid biopsy. The 
current treatment approach for melanoma is based on evaluating disease progression, 
followed by treatment modification to potentially improve patient outcomes and 
discontinue ineffective therapy. Our data suggest that an observation period may be 
required prior to conclusive evaluation of therapeutic benefits to immunotherapy and 
treatment modification decisions. 
While ctDNA was found to be a reliable prognostic and surveillance biomarker, it is not 
without limitations. A significant roadblock for ctDNA analysis in this study was the low 
detection rate of ctDNA prior to anti-PD-1 and/or anti-CTLA-4 treatment compared with 
targeted therapy. As indicated above, most patients with detectable ctDNA have 
prominent visceral metastases, particularly to the liver. The variation of tumour cell 
turnover at different metastatic sites may have an impact on the detectability of ctDNA. 
In addition, the low detection rate may have been affected by the specificity of the assay 
used for ctDNA analysis. Aside from our in-house BRAF assays, which have been 
previously reported to have high specificity and sensitivity [263], assays for other 
mutations have a lower limit of detection due to noise [234]. Differences in assay 
threshold may also affect the detection rate of ctDNA in melanoma patients treated with 
immune-checkpoint inhibitors. Thus, the site of metastases and the assay specificity of 
the mutational target for ctDNA analysis appears to highly influence the variation in the 
detection rate observed in this study. 
Previous studies have demonstrated the predictive value of tissue-derived mutational 
and neoepitope load for immunotherapy response in NSCLC [318, 319] and melanoma 
[323]. In this study, we also explored the potential utility of ctDNA for mutational and 
neoepitope load analysis in melanoma. Gandara et al. [322] demonstrated the utility of 
blood tumour mutational burden as a clinically-actionable biomarker for anti-PD-L1 in 
NSCLC. Similarly, our exploratory analysis also demonstrated that whole exome sequence 
(WES)-defined molecular analysis for clarifying tumour mutational burden in ctDNA is 
possible. In our cohort, mutational load was unable to discriminate between responders 
and non-responders to anti-PD-1 inhibitor. Nonetheless, we observed a trend showing 
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high neoepitope load in patients that achieved clinical benefit to anti-PD-1 blockade. The 
small sample size was not sufficient to discriminate between responders and non-
responders to immunotherapy. These findings may be confounded by the small sample 
size mostly consisting of patients with high levels of ctDNA (>7% frequency abundance). 
WES analysis imposed the need to select for patients with high ctDNA fraction, which 
excluded most samples in our cohort. On the other hand, mutational burden derived from 
targeted sequencing has been previously shown to be sufficient for stratifying responders 
and non-responders to immunotherapy [322]. Thus, a targeted approach, with the 
addition of unique molecular identifiers (UMI), may be more fitting for ctDNA mutational 
burden analysis, as it will be able to control for PCR errors and allow interrogation of 
variants at low allelic fraction (<1%). 
In conclusion, ctDNA has significant clinical value as a biomarker of prognosis and 
therapeutic response for melanoma. Nonetheless, limitations inherent to ctDNA analysis 
need to be clearly defined and thoroughly addressed prior to its implementation in the 
clinic. 
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5.8 Supplementary Material 
Figure S5.1. Kinetics of ctDNA decay. Time course of biological response for patients undergoing first or second-line treatment with (a) anti-CTLA-4 
(N=8), (b) anti-CTLA-4 plus anti-PD-1 (N=8), (c) anti-PD-1 (N=21) or (d) targeted therapy (BRAF/MEKi) (N=47). Solid lines in green, orange and red 
denotes treatment responders, stable disease and non-responders, respectively. Solid lines in green with red symbol represents patients that 
developed resistance to targeted therapy. 
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 Group A Group B Group C Total Group A Group B Group C Total 
Variable N=14 (%) N=8 (%) N=7 (%) N=29 (%) N=11 (%) N=33 (%) N=3 (%) N=47 (%) 
Age           
≤65 5 (36) 6 (75) 3 (43) 14 (48) 
0.196 
5 (45) 18 (55) 2 (67) 25 (53) 
0.775 
>65 9 (64) 2 (25) 4 (57) 15 (52) 6 (55) 15 (45) 1 (33) 22 (47) 
Gender           
Female 3 (21) 1 (12) 4 (57) 8 (28) 
0.120 
5 (45) 10 (30) 1 (33) 16 (34) 
0.655 
Male 11 (79) 7 (88) 3 (43) 21 (72) 6 (55) 23 (70) 2 (67) 37 (66) 
M Classification           
M1a/M1b 9 (67) 2 (25) 1 (14) 12 (41) 
0.049 
2 (18) 9 (27) 1 (33) 12 (26) 
0.794 
M1c/M1d 5 (36) 6 (75) 6 (86) 17 (59) 9 (82) 24 (73) 2 (67) 35 (74) 
Brain metastasis           
Yes 3 (21) 2 (25) 1 (14) 6 (21) 
0.873 
6 (55) 5 (15) 1 (33) 12 (26) 
0.032 
No 11 (79) 6 (75) 6 (86) 23 (79) 5 (45) 28 (85) 2 (67) 36 (74) 
Brain only metastasis           
Yes 2 (14)   2 (7) 
N/A 
2 (18)   2 (4) 
N/A 
No 12 (86) 8 (100) 7 (100) 27 (93) 9 (82) 33 (100) 3 (100) 45 (96) 
ECOG status           
0 9 (64) 3 (37.5) 3 (43) 15 (52) 
N/A 
8 (73) 16 (48) 2 (67) 26 (55) 
N/A 
1,2,3 3 (22) 3 (37.5) 3 (43) 9 (31) 1 (9) 5 (15)  6 (13) 
Not available 2 (14) 2 (25) 1 (14) 5 (17) 2 (18) 12 (36) 1 (33) 15 (32)  
LDH levels           
Normal 7 (50) 2 (25) 1 (14) 10 (34) 
N/A 
8 (73) 13 (39)  21 (44) 
N/A 
Abnormal 1 (7) 4 (50) 3 (43) 8 (28)  13 (39) 1 (33) 14 (30) 
Not available 6 (43) 2 (25) 3 (43) 11 (38)  3 (27) 7 (22) 2 (67) 12 (26)  
Prior lines of therapy           
Yes 6 (43) 4 (50) 1 (14) 11 (38) 
0.316 
1 (6) 2 (6)  3 (6) 
N/A 
No 8 (57) 4 (50) 6 (86) 18 (62) 10 (94) 31 (94) 3 (100) 44 (94) 
BRAF mutational status           
BRAF Mutant 6 (43) 2 (25) 1 (14) 9 (31) 
0.373 
11 (100) 33 (100) 3 (100) 47 (100) 
N/A 
BRAF WT 8 (57) 6 (75) 6 (86) 20 (69)     
N/A: not applicable.  
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Table S5.2. Multivariate Cox proportional-hazards regression analysis for associations between ctDNA levels and survival. 
Group A/B/C Immunotherapy Group A/B Targeted Therapy 
Variables 
Progression free survival Overall survival Progression free survival Overall survival 
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Age (≤65 vs. >65) 0.34 (0.73 - 1.61) 0.175 0.51 (0.11 - 2.48) 0.407 1.41 (0.64 - 3.05) 0.388 1.82 (0.68 - 4.87) 0.228 
Gender (female vs. male) 0.87 (0.21 - 3.69) 0.851 10.02 (1.27 - 78.71) 0.028 1.17 (0.52 - 2.62) 0.694 0.87 (0.31 - 2.39) 0.792 
M Classification (M1a/b vs. M1c/d) 0.95 (0.19 - 4.62) 0.956 5.94 (0.63 - 55.78) 0.119 0.80 (0.32 - 2.02) 0.650 1.24 (0.37 - 4.19) 0.720 
Brain metastasis (yes vs. no) 3.76 (0.71 - 19.85) 0.118 1.95 (0.33 - 11.49) 0.459 3.05 (1.09 - 8.54) 0.034 5.25 (1.34 - 20.50) 0.017 
Brain only metastasis (yes vs. no) - - - - 10.04 (1.27 - 79.27) 0.029 14.20 (1.48 - 136.34) 0.021 
Prior lines of therapy (yes vs. no) 0.84 (0.08 - 8.05) 0.881 0.12 (0.004 - 3.73) 0.228 0.64 (0.15 - 2.67) 0.542 0.23 (0.02 - 2.07) 0.191 
BRAF mutational status (mut vs. WT) 1.45 (0.13 - 15.48) 0.758 6.32 (0.21 - 189.11) 0.287 - - - - 
ctDNA levels 
- ctDNA kinetics group
      Group A vs. 
      Group B 
      Group C 
1 
1.91 (0.32 - 11.22) 




0.98 (0.13 - 7.17) 










































































































MP0104 BRAF Mut Pembrolizumab PR Yes (Ipilimumab) 25/08/2014 29/08/2016 105 x 
MP0105 BRAF WT Pembrolizumab CR Yes (Ipilimumab) 10/02/2015 29/12/2017 150 x x x 
MP0201 BRAF Mut Pembrolizumab CR 
No 
(Radiation Therapy) 
5/08/2016 27/02/2018 82 x x x 
MP0303 BRAF Mut Pembrolizumab PR No 15/09/2017 Ongoing 90a x x 
MP0302 BRAF Mut Pembrolizumab SD No 13/12/2017 31/05/2018 24 x x x 
MP0102 BRAF WT Pembrolizumab PD No 10/12/2015 12/02/2016 9 x x x 
MP0103 BRAF Mut Pembrolizumab PD No 13/05/2016 4/07/2016 7 x x x 
MP0301 BRAF WT Pembrolizumab PD No 11/06/2015 18/09/2015 14 
MP0304 BRAF WT Pembrolizumab PD No 03/04/2017 25/05/2017 7 x x x 





Table S5.4. Demographic, clinicopathologic, and treatment characteristics of included samples. 
Variable 
            All samples 






20-49 11 (15) 20 (29) 
50-69 38 (53) 31 (44) 
70-99 23 (32) 19 (27) 
Sex 
Female 18 (25) 25 (36) 
Male 54 (75) 45 (64) 
M Classification 
M1a 16 (22) 15 (21) 
M1b 7 (10) 6 (9) 
M1c 31 (43) 32 (46) 
M1d 18 (25) 17 (24) 
Mutational Status 
BRAF Mutant 30 (42) 70 (100) 
NRAS Mutant 20 (28)   
Others 22 (30)   
Treatment 
Anti-PD1 inhibitor     
      Pembrolizumab 40 (56)   
      Nivolumab 1 (1)   
Anti-CTLA-4 inhibitor     
      Ipilimumab 12 (17)   
Anti-PD-1 plus anti-CTLA-4 
inhibitor 
    
      Ipilimumab/Nivolumab 19 (26)   
BRAFi     
      Vemurafenib   4 (6) 
      Dabrafenib   1 (1.5) 
BRAFi plus MEKi    
      Dabrafenib/Trametinib   64 (91) 
      Vemurafenib/Cobimetinib   1 (1.5) 
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Table S5.5. Specificity of ddPCR assays. 
Assay 
Healthy controls 
Maximum false positive concentration (copies/mL) 
Positive Negative 
BRAF V600E2 1 12 1 
BRAF K601E 3 7 2 
BRAF L597Q 0 16 0 
NRAS Q61R 7 24 9 
NRAS G12D 4 6 3 
NRAS G13D 4 6 5 
GRM3 E538K 0 10 0 
GRM3 S491L 6 12 6 
FLT1 E011K 3 7 9 
TP53 R158H 1 9 2 
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CHAPTER 6. PLASMA CTDNA FAILS TO RELIABLY DETECT 
CLINICAL PROGRESSION IN METASTATIC MELANOMA PATIENTS 
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CHAPTER 7. GENERAL DISCUSSION AND FUTURE DIRECTIONS 
Plasma ctDNA is currently considered a promising biomarker of disease status for 
metastatic cancer [275, 316, 358]. In this context, the studies in this thesis evaluated the 
validity of ctDNA analysis across the whole spectrum of metastatic melanoma 
management: i) molecular profiling prior to therapy initiation to aid targeted therapy 
selection (Chapter 3), ii) prognostic and predictive potential of baseline ctDNA levels 
(Chapter 4), iii) monitoring response to treatment (Chapter 5) and iv) detection of 
disease progression (Chapter 6) (Figure 7.1). 
 
Figure 7.1. Applications of ctDNA analysis during metastatic melanoma management. 
Detection of ctDNA requires highly sensitive and specific assays, especially in patients 
with low tumour burden. In melanoma, multiple studies have relied on a single mutation 
targeted approach for ctDNA analysis using droplet-based PCR systems, particularly 
ddPCR and BEAMing. Both methods generally target a single mutation at a time and have 
been shown to have a substantially high analytical sensitivity compared to other ctDNA 
detection assays [359]. Direct comparison of ddPCR and BEAMing indicated a high 
agreement (κ = 0.87; 95% CI, 0.81–0.93) [360]. Therefore, the use of ddPCR for ctDNA 
detection through these studies is in line with current best practice. 
Given that a large proportion of melanomas carry hotspot mutations in BRAF or NRAS 





time. For individuals that do not harbour these common variants, sequencing of tumour 
samples is necessary to identify mutational targets for ctDNA analysis by ddPCR [234]. 
In Chapter 2, we described an optimal and reproducible cfDNA extraction [249-251] and 
testing protocol that enables sensitive and specific detection and quantification of ctDNA 
from plasma samples. This ddPCR assay has been the primary approach used in the 
studies comprising this thesis. 
In addition to the sensitivity of each assays, it is also apparent that pre-analytical factors 
can significantly affect ctDNA detection rate [243, 244, 355, 361]. Importantly, ctDNA 
studies should report on the conditions in plasma separation and storage, transport and 
cfDNA extraction to allow comparison to be made between studies. To provide robust 
and comparable results, Chapter 2 outlines the use of optimal blood collection tubes [246] 
and the most efficient column-based cfDNA extraction method, previously vetted by the 
CANCER-ID consortium study. The study compared the extraction efficiency of 6 different 
cfDNA extraction kits from a total of 17 independent laboratories and concluded that the 
QIAamp Circulating Nucleic Acid kit showed the highest recovery, independent of the 
blood collection tube used [247]. 
Using a multiplex BRAF assay for ddPCR, the study in Chapter 3 demonstrated a high 
degree of concordance between standard-of-care tumour-based BRAF mutation profiling 
and plasma-based testing. The positive agreement was found to be 78% and an overall 
agreement of 88%, supporting the results of multiple other studies [216, 218, 224, 225, 
362]. Nevertheless, it is important to note that undetectable mutant BRAF ctDNA, without 
prior knowledge of the patients’ BRAF status, does not preclude the possibility that the 
variant is either absent in the tumour or that there was an insufficient amount of ctDNA 
present in the specimen. This has been recognised as a major limitation for the use of 
ctDNA for tumour genotyping [276]. Accordingly, while the FDA and the EMA approved 
the ctDNA test for detection of the EGFR p.T790M resistance mediating mutation in 
(NSCLC), undetectable ctDNA results have to be followed by the use of a tissue biopsy to 
confirm the absence of the mutation [276]. In line with this recommendation, if BRAF 
genotyping is to be pursued through ctDNA profiling, a negative result will need 
confirmation on a tumour sample before a patient can be deemed BRAF-mutant negative 





Chapter 3 also presents an attempt to model the potential economic benefit of BRAF 
profiling through cfDNA testing. We calculated that savings of at least $36,238 per annum 
could be incurred if BRAF cfDNA testing was performed instead of tumour biopsy 
analyses, representing a reduction of 22% on the overall expense of BRAF testing. These 
results support the inclusion of ctDNA analysis to establish tumour genotype prior to 
treatment with targeted therapies is to be considered. 
The main advantage of cfDNA analysis is that it offers an alternative route for assessing 
BRAF status in cases where metastases are widespread and tissue biopsy is not possible 
or does not yield sufficient material for testing. Additionally, the high prevalence of 
activating BRAF mutations in colorectal, thyroid, and ovarian cancers [289], as well as 
clinical trials with targeted therapies [290, 291], enable its use beyond melanoma. 
Moreover, BRAF mutation tests may become relevant to other cancer types that receive 
regulatory approval for the use of BRAF inhibitor therapy. 
Despite the encouraging results presented in this thesis, obtaining a tissue sample for 
molecular profiling is not typically a major obstacle in metastatic melanoma, as biopsies 
are commonly performed to confirm the disease. Therefore, although ctDNA testing for 
BRAF detection is clinically valid, in practice it will only be useful and cost-effective in a 
minority of cases. For example, for cases where a tumour biopsy will involve a very 
invasive procedure, the patient has significant comorbidities and there is a need for a 
rapid tumour turnaround for treatment decision [219]. Similarly, it is not uncommon that 
FNA procedures yield insufficient or unsuitable tumour material for genotyping, and in 
such cases, a rapid and minimally invasive ctDNA testing may provide critical information 
to inform treatment course. 
Limited economic studies have investigated the use of this liquid biopsy in oncology and 
most of them have shown only a moderate to no economic benefit [363-365]. These 
results underscore the reality that the implementation of ctDNA analysis into clinical 
practice necessitates thorough cost-effectiveness calculations to further support its 
clinical utility [366]. The economic benefit must be related to each specific context of use 
for ctDNA analysis in the management of cancer, i.e. prognostication for early 
intervention, genotyping for treatment selection or disease monitoring. Notwithstanding 





benefit, which for most applications would be ultimately an improvement in survival. 
However, survival benefits also depend on the efficacy of the associated therapeutic 
intervention. Thus, it is only through careful study designs and/or large clinical trials that 
incorporate ctDNA results to inform treatment decisions, that the health economic 
benefit of liquid biopsies can be accurately assessed and their regulatory approval can 
move forward. 
Currently, treatment selection and monitoring a patient’s disease course during therapy 
are considered important priorities for melanoma management. It is in this context that 
a liquid biopsy may have the biggest impact. Once the mutation profile has been 
identified, first-line selection treatment by the medical professionals involves accounting 
for multiple factors such as median tumour size, LDH levels, BRAF status, presence of 
brain metastases and comorbidities that must be carefully considered [136, 309, 310]. 
In Chapter 4, we analysed the ability of ctDNA to assist with treatment selection and 
patient stratification. Similar to previous studies, we found that high ctDNA levels are 
associated with poorer clinical outcomes [12, 15, 187, 193], while a low baseline ctDNA 
level correlated with tumour shrinkage on radiology [213] and longer PFS in melanoma 
patients treated with immunotherapies [14]. By contrast, Lee et al. showed that a decline 
in ctDNA level during treatment, but not low concentration at baseline, was predictive of 
longer PFS and OS [217]. This may be due to the inclusion of a large proportion of patients 
receiving immunotherapy in the second-line setting. 
Indeed, we found that the predictive value of ctDNA was lost in the second-line treatment 
setting, particularly in patients failing first-line targeted therapy. Importantly, these 
findings were validated using an independent cohort of patients with samples collected 
and analysed in laboratories of collaborators in Sydney and Melbourne. Diverse factors 
arising at disease progression including the presence of brain metastases and the 
decreased response to second-line therapy may limit the prognostic value of ctDNA in 
pre-treated patients. Therefore, the prognostic potential of ctDNA must be taken with 
caution in this population. Future studies evaluating ctDNA detectability in relation to 
previous systemic therapy and anatomical tumour location are also necessary. Moreover, 
there is a need to understand the origin of ctDNA and the cellular dynamics that govern 





A novel finding of the study described in Chapter 4, was the observation that patients 
with high pre-treatment ctDNA levels had better outcomes if treated with the 
combination of anti-CTLA-4 and anti-PD-1 as first-line therapy. Although ctDNA levels 
correlate significantly with tumour burden [16, 235], multivariate analyses in previous 
studies have shown ctDNA to be a stronger and independent predictor of survival than 
tumour burden [201, 211, 212, 217, 235]. In this context, our results suggest that more 
aggressive combination treatment will be particularly beneficial to those patients with 
high ctDNA levels. On the other hand, patients with low or undetectable ctDNA may be 
treated with anti-PD-1 monotherapy, which is associated with less adverse events [369, 
370]. However, we should note that the observation regarding patients with high ctDNA 
levels benefiting from combination immunotherapy, was the result of a post-hoc analysis 
combining both cohorts. Therefore the study was not appropriately designed or powered 
to strongly reaffirm this conclusion. A prospective clinical trial is needed to confirm our 
observations and validate the use of ctDNA to guide immunotherapy selection. 
In Chapter 5, the study defines that decreasing ctDNA levels early during treatment is a 
strong predictor of clinical outcome. In particular, high levels of ctDNA prior to treatment 
and early during therapy were indicative of poor survival outcome, while patients with 
undetectable ctDNA at baseline had a longer time to progression irrespective of 
treatment. These results are supported by previous findings [214, 215, 217, 371] in 
patients treated with immunotherapy and further demonstrated the capacity of ctDNA to 
accurately monitor treatment response and predict clinical outcome in a large cohort of 
melanoma patients. These findings underscore the suitability of ctDNA as a prognostic 
biomarker for the currently available treatments of melanoma patients. Moreover, the 
ability of undetectable or decreasing ctDNA levels to accurately distinguish between true 
progression or pseudoprogression has also been investigated [218]. This ambiguous 
pattern of response, described as an initial increase in size of tumour lesions followed by 
a delayed partial response, can hinder accurate report of response in patients treated 
with immunotherapies [372]. In this setting, ctDNA can provide critical clinical 
information. 
The need of ctDNA analysis beyond BRAF and NRAS mutations becomes critical for 
melanoma subtypes other than cutaneous since they are known to carry different driver 





proportions of KIT and NF1 mutations [373], which are not restricted to singular 
hotspots. In addition to point mutations, acral and mucosal melanomas are commonly 
associated with copy number alterations. A study monitoring copy number alterations in 
acral and mucosal cfDNA, found that plasma copy number ratio was correlated with 
clinical response or progression [374]. Uveal melanomas carry mutually exclusive 
activating mutations in GNAQ, GNA11, PLCβ4, and CYSLTR2, accounting for more than 
90% of all uveal patients [375-377]. Various studies have utilised these ctDNA mutations 
to track uveal melanoma evolution and monitor treatment response [378, 379]. 
The increased number of therapies available to treat melanoma requires the stratification 
of patients into appropriate treatments, stressing the importance of regular monitoring 
for timely detection of disease progression and adjustment of treatment. Current clinical 
surveillance and monitoring are performed by regular blood tests and expensive imaging 
technologies, which are utilised for efficient detection of progressive metastatic disease. 
The results presented in Chapter 6 revealed that ctDNA was not reliable for the detection 
of disease progression when compared with imaging technologies. We found that in 47% 
of the cases, ctDNA failed to detected disease progression. Our results are, in contrast 
with other studies indicating a high ctDNA detection rate at the time of progression (51% 
and 100%) and that an increasing ctDNA level is pre-emptive of clinical progression, with 
a calculated lead time of 25 and 21 weeks [224, 225]. Furthermore, Váraljai et al. 
described that in 86% of the 36 melanoma patients that did not show response to 
systemic treatment, ctDNA increase preceded radiological progression with an average 
lead-time window of 3.5 months [347]. 
A few factors that could explain the lower ctDNA detection rate at progression reported 
in this thesis must be mentioned. Firstly, the studies defined above are comprised of 
smaller cohorts that used BEAMing technology for ctDNA detection [224, 225]. 
Nevertheless, previous studies indicated that BEAMing has the same level of sensitivity 
as ddPCR [360]. Secondly, and possibly the critical point, previous studies have compared 
ctDNA to CT scan-based progression by RECIST. On the other hand, PET scans are the 
modality of choice for disease monitoring in Australia and the one used in our studies. Of 
note, published studies have shown that CT scans are less sensitive than PET scans for 
detection of metastatic lesions [380, 381]. Thirdly, the ability of ctDNA to detect 





copies. While this point is controversial and some researchers have suggested to perform 
a t-test of the triplicate results, we chose to do a Poisson test, in line with the nature of a 
ddPCR quantification [382]. Herbreteau et al. [216] was the first study to calculate the 
significance of changes in ctDNA levels using Poisson analysis. Similarly, we have 
developed a method in Chapter 4 and Chapter 6 that quantifies significant changes in 
ctDNA levels. Ultimately, this study highlights the need to develop specific criteria when 
evaluating response or progression by changes in ctDNA levels. 
Previous studies by our group and others have shown that ctDNA correlates with tumour 
size [12, 14, 209, 210] and more strongly with MTB [235]. However, we observed that 
ctDNA levels did not correlate with MTB at the time of progression compared to the 
analysis at baseline (Figure 6.4). This finding may support the observation in Chapter 4 
that ctDNA levels at the time of starting second-line treatment, i.e. at progressive disease 
to first-line therapy, fail to accurately provide prognostic information. Notably, both 
studies were evaluated in the context of targeted therapies as first-line treatment, 
underscoring the need of additional studies investigating how the pathological state of 
the tumour and resistance mechanisms to MAPK inhibition may affect ctDNA release. In 
this context, melanomas might undergo metabolic reprogramming at the time of 
progression to therapy [383] and important changes in the microenvironment of the 
tumour lesions might reduce the shedding of ctDNA into the bloodstream. 
Across all the studies in this thesis, we highlighted an important limitation of ctDNA 
analysis: the lack of or limited ctDNA shedding in patients with disease restricted to the 
brain. This represents a critical issue, as current studies have shown that a high 
proportion of BRAF mutant patients that progress to first-line targeted therapy present 
with brain metastases [302], with 20% of patients presenting only intracranial 
progression [384], often contributing to death [308, 385]. Given that brain metastases 
have been reported to shed less ctDNA into the bloodstream [192, 300], the large 
proportion of disease progression within the brain may contribute to the limited 
predictive value of baseline ctDNA and the low ctDNA detection rate in patients with 
intracranial disease only. Notably, in the case of brain metastatic lesions, ctDNA can be 
found in the cerebrospinal fluid providing an alternative source for liquid biopsies [282, 
344]. However, the complexity and invasiveness of lumbar puncture can be a significant 





Most studies of ctDNA in melanoma have mainly monitored singular specific mutations 
using highly sensitive targeted assays. However, the use of a limited number of variants 
in these studies may have hampered our ability to capture the full genetic heterogeneity 
present in melanoma tumours. Moreover, it is critical to notice that promoter mutation 
targets, such as TERT, have been observed to be under-represented in cfDNA fractions 
[16, 257]. Therefore, the analysis of multiple mutations in the same sample could 
significantly increase ctDNA detection levels. The recent development of next-generation 
sequencing panels that target melanoma-specific mutations has previously been shown 
to derive a reliable concordance of mutations between tumour tissue and blood samples 
[234, 386]. The continuous development of these assays will continue to support the 
suitability of ctDNA analysis for genetic profiling, especially in patients that do not carry 
a primary BRAF mutation. 
A major limitation on our approach for ctDNA analysis is the use of targeted assays, 
commonly restricted to one mutation per patient. The use of these assays is important 
when identifying variants associated with response to drugs, such as BRAF in melanoma 
[74] or EGFR in non-small cell lung cancer [387]. The common use of this oncogenic driver 
mutation has been described as reliable and stable in ctDNA, with relapsing tumours 
maintaining their reliance on these key oncogenic drivers [388]. Moreover, we employed 
a tumour-informed approach to determine a key mutation to track disease in patients 
with BRAF WT melanomas. However, it is possible that factors such as clonality and 
oncogenic dependence may affect their frequency abundance in the tumours and 
therefore their concentration in plasma. For example, the development of clonal 
evolution with the rise of secondary mutations that mediate resistance is affected by 
treatment with targeted agents [13] and cfDNA can accurately reveal different sub-clonal 
responses to therapy [389] and escape mechanisms such as BRAF amplification [234]. 
The analysis of multiple variants will not only enable a more accurate disease assessment 
but also increase our ability to detect tumoral DNA. Recently, the development of genomic 
technologies has enabled the testing and monitoring of multiple tumour-specific 
mutations in a single assay. 
The MassArray System, which utilises mass spectrometry to accurately measure PCR-





different mutational targets for ctDNA detection and monitoring [188, 234]. 
Nevertheless, each of the targets remains constrained to single mutational changes. On 
the other hand, targeted sequencing can be used to study small regions, such as, 
individual exons, or a larger number of loci, expanding our ability to detect multiple genes 
of interest [194-197]. 
Analysis of ctDNA using targeted NGS requires incorporation of UMIs, which enable error 
suppression and detection of low frequency mutations [390]. Nevertheless, the high 
cfDNA input required, overall cost and lack of standardisation of the analysis pipelines 
associated with these technologies, limit their use to the research settings. Current 
studies are exploring the use of these assays in various tumour types and future cost 
reductions and validations will enable its implementation in ctDNA detection [391]. 
Beyond mutational analysis on ctDNA, the development of tests such as CancerSEEK that 
combine protein with genetic biomarkers has the potential to increase sensitivity [392], 
and may significantly increase the detection rate of residual disease and pathological 
progression. Furthermore, others studies have reported on multiparametric assays that 
include supplementary cancer biomarkers, such as metabolites, mRNA transcripts, 
miRNAs or methylated DNA sequences, can increase the detection rate and help to 
accurately identify malignancy from a single blood sample [236]. 
Altogether, ctDNA analysis has a unique place in the management of melanoma. This 
minimally invasive modality can rapidly determine the mutation status prior to 
treatment initiation, serve as a prognostic biomarker in the first-line therapy setting and 
indicate response early during therapy. However, here we show that this liquid biopsy 
only detects disease progression in half of the patients when compared to sensitive 
imaging technologies and has no prognostic value in the second-line setting. 
Studies such as the ones presented in this thesis are important to inform design and 
support the development of randomised ctDNA-based interventional clinical trials. 
Currently, multiple clinical trials aim at validating the role of ctDNA as a predictive 
biomarker across different tumour types and status of disease [393]. Notably, the 
MELCIRC trial (NCT02862743) is currently investigating the concordance between 
mutations in ctDNA and tumour tissue, as well as the prognostic impact of the ctDNA 





to evaluate whether ctDNA can aid effective switching from targeted to immune therapy 
based on ctDNA decline, early during treatment. 
Interest in ctDNA has been increasing during the last decade, especially in the oncology 
setting. However, there is a crucial need to increase the consistency between the 
protocols used in handling the sample and the techniques used for analysis and reporting 
the results. The research presented here stresses the need to develop a uniform and 
standard template for plasma isolation and storage, ctDNA analysis and interpretation of 
results. Such protocol will allow for the easy integration of this biomarker into clinical 
trials by providing clear rules on the optimal pre-analytical steps and ctDNA 
quantification platforms. In addition, strict collection windows should be applied in order 
to make head-to-head comparison between ctDNA and imaging techniques possible. The 
use of ctDNA in melanoma should follow the path of other malignancies such as the recent 
ctDNA applications in colorectal cancer whitepaper [394]. Ultimately, the growing body 
of work and evidence in the expanding field will clear the way for implementing ctDNA 
analysis into routine clinical management [395] and improve cancer care through 
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